



**RETURN BIDS TO:
RETOURNER LES SOUMISSIONS À:**

**Bid Receiving - PWGSC / Réception des
soumissions - TPSGC**
11 Laurier St. / 11, rue Laurier
Place du Portage , Phase III
Core 0B2 / Noyau 0B2
Gatineau, Québec K1A 0S5
Bid Fax: (819) 997-9776

**REQUEST FOR PROPOSAL
DEMANDE DE PROPOSITION**

**Proposal To: Public Works and Government
Services Canada**

We hereby offer to sell to Her Majesty the Queen in right of Canada, in accordance with the terms and conditions set out herein, referred to herein or attached hereto, the goods, services, and construction listed herein and on any attached sheets at the price(s) set out therefor.

**Proposition aux: Travaux Publics et Services
Gouvernementaux Canada**

Nous offrons par la présente de vendre à Sa Majesté la Reine du chef du Canada, aux conditions énoncées ou incluses par référence dans la présente et aux annexes ci-jointes, les biens, services et construction énumérés ici sur toute feuille ci-annexée, au(x) prix indiqué(s).

Comments - Commentaires

Vendor/Firm Name and Address

**Raison sociale et adresse du
fournisseur/de l'entrepreneur**

Issuing Office - Bureau de distribution

Drugs, Vaccines and Biologics Division/Div.des produits
pharmaceutiques,biologiques et de vaccins
Terrasses de la Chaudière 5th Floor
10 Wellington Street
Gatineau
Quebec
K1A 0S5

Title - Sujet Multi-source pharmaceuticals	
Solicitation No. - N° de l'invitation E60PH-19DRUG/A	Date 2019-05-15
Client Reference No. - N° de référence du client E60PH-19DRUG	
GETS Reference No. - N° de référence de SEAG PW-\$\$PH-895-77093	
File No. - N° de dossier ph895.E60PH-19DRUG	CCC No./N° CCC - FMS No./N° VME
Solicitation Closes - L'invitation prend fin at - à 02:00 PM on - le 2019-05-31	Time Zone Fuseau horaire Eastern Daylight Saving Time EDT
F.O.B. - F.A.B. Specified Herein - Précisé dans les présentes Plant-Usine: <input type="checkbox"/> Destination: <input type="checkbox"/> Other-Autre: <input checked="" type="checkbox"/>	
Address Enquiries to: - Adresser toutes questions à: Bissonnette(ph895), Suzanne	Buyer Id - Id de l'acheteur ph895
Telephone No. - N° de téléphone (819) 360-4895 ()	FAX No. - N° de FAX () -
Destination - of Goods, Services, and Construction: Destination - des biens, services et construction: See Herein	

Instructions: See Herein

Instructions: Voir aux présentes

Delivery Required - Livraison exigée	Delivery Offered - Livraison proposée
Vendor/Firm Name and Address Raison sociale et adresse du fournisseur/de l'entrepreneur	
Telephone No. - N° de téléphone Facsimile No. - N° de télécopieur	
Name and title of person authorized to sign on behalf of Vendor/Firm (type or print) Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie)	
Signature	Date

TABLE OF CONTENTS

MULTI-SOURCE PHARMACEUTICALS

PART 1 - GENERAL INFORMATION

- 1.1 Security Requirement
- 1.2 Requirement
- 1.3 Debriefings
- 1.4 Trade Agreements
- 1.5 Phased Bid Compliance Process
- 1.6 epost Connect service

PART 2 - BIDDER INSTRUCTIONS

- 2.1 Standard Instructions, Clauses and Conditions
- 2.2 Submission of Bids
- 2.3 Enquiries - Bid Solicitation
- 2.4 Applicable Laws
- 2.5 Offers from Agents, Dealers or other Resale Outlets
- 2.6 Distribution by a Third Party
- 2.7 Disclosure of Information - Federal Government Quantities and Pharmaceutical Prime Vendor Standing Offer Holder

PART 3 - BID PREPARATION INSTRUCTIONS

- 3.1 Bid Preparation Instructions
- 3.2 Section I: Technical Bid
- 3.3 Section II: Financial Bid
- 3.4 Section III: Certifications

PART 4 - EVALUATION PROCEDURES AND BASIS OF SELECTION

- 4.1 Evaluation Procedures
- 4.2 Basis of Selection

PART 5 - CERTIFICATIONS AND ADDITIONAL INFORMATION

- 5.1 Certifications Required with the Bid
- 5.2 Certifications Precedent to Contract Award and Additional Information

PART 6 - RESULTING CONTRACT CLAUSES

- 6.1 Security Requirement
- 6.2 Requirement
- 6.3 Standard Clauses and Conditions
- 6.4 Term of Contract
- 6.5 Authority
- 6.6 Authorized Agents
- 6.7 Ordering
- 6.8 Packaging
- 6.9 Payment
- 6.10 Invoicing Instructions
- 6.11 Product Recall or Withdrawal
- 6.12 Returns
- 6.13 Notice of Anticipated Shortage
- 6.14 Inability to Supply
- 6.15 Reporting
- 6.16 Certifications

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

- 6.17 Federal Contractor's Program
- 6.18 Applicable Laws
- 6.19 Priority of Documents
- 6.20 Defence Contract
- 6.21 Insurance

List of Annexes:

- Annex A Requirement, Pricing and Deliverables
- Annex B Identified Users and Delivery Points
- Annex C Example of Periodic Reports
- Annex D: Return Policy
- Annex E: Mandatory Technical Criteria
- Annex F: Financial Offer
- Annex G: Federal Contractor's Program –Employment Equity
- Annex H: Electronic Payments Instruments

Forms:

- Form 1 Bid Submission

PART 1 - GENERAL INFORMATION

MULTI-SOURCE PHARMACEUTICALS

1.1 Security Requirement

There is no security requirement associated with this bid solicitation.

1.2 Requirement

The requirement is detailed under Article 6.2 of the resulting contract clauses.

1.3 Debriefings

Bidders may request a debriefing on the results of the bid solicitation. Bidders should make the request to the Contracting Authority within 15 working days from receipt of the results of the bid solicitation process. The debriefing may be provided in writing, by telephone or in person.

1.4 Trade Agreements

The requirement is subject to the Canadian Free Trade Agreement (CFTA).

1.5 Phased Bid Compliance Process

The Phased Bid Compliance Process (PBCP) applies to this requirement.

1.6 epost Connect service

This bid solicitation allows bidders to use the epost Connect service provided by Canada Post Corporation to transmit their bid electronically. Bidders must refer to Part 2 entitled Bidder Instructions, and Part 3 entitled Bid Preparation Instructions, of the bid solicitation, for further information.

PART 2 - BIDDER INSTRUCTIONS

2.1 Standard Instructions, Clauses and Conditions

- (a) All instructions, clauses and conditions identified in the bid solicitation by number, date and title are set out in the Standard Acquisition Clauses and Conditions Manual (<http://buyandsell.gc.ca/policy-and-guidelines/standard-acquisition-clauses-and-conditions-manual>) issued by Public Works and Government Services Canada.
- (b) Bidders who submit a bid agree to be bound by the instructions, clauses and conditions of the bid solicitation and accept the clauses and conditions of the resulting contract.
- (c) The 2003 (2018-05-22) Standard Instructions - Goods or Services - Competitive Requirements, are incorporated by reference into and form part of the bid solicitation.

2.2 Submission of Bids

Bids must be submitted only to PWGSC Bid Receiving Unit by the date, time and place indicated on page 1 of the bid solicitation.

2.3 Enquiries - Bid Solicitation

All enquiries must be submitted in writing to the Contracting Authority no later than five (5) calendar days before the bid closing date. Enquiries received after that time may not be answered.

Bidders should reference as accurately as possible the numbered item of the bid solicitation to which the enquiry relates. Care should be taken by Bidders to explain each question in sufficient detail in order to enable Canada to provide an accurate answer. Technical enquiries that are of a proprietary nature must be clearly marked "proprietary" at each relevant item. Items identified as "proprietary" will be treated as such except where Canada determines that the enquiry is not of a proprietary nature. Canada may edit the question(s) or may request that the Bidder do so, so that the proprietary nature of the question(s) is eliminated, and the enquiry can be answered to all Bidders. Enquiries not submitted in a form that can be distributed to all Bidders may not be answered by Canada.

2.4 Applicable Laws

Any resulting contract must be interpreted and governed, and the relations between the parties determined, by the laws in force in the province of Ontario.

Bidders may, at their discretion, substitute the applicable laws of a Canadian province or territory of their choice without affecting the validity of their bid, by deleting the name of the Canadian province or territory specified and inserting the name of the Canadian province or territory of their choice. If no change is made, it acknowledges that the applicable laws specified are acceptable to the Bidders.

2.5 Offers from Agents, Dealers or other Resale Outlets

If the Bidder is not the manufacturer of the items offered, but is bidding on behalf of a prime manufacturer, in addition to the other requirements of this bid solicitation, it is mandatory upon request that the Bidder submit a letter of authorization, confirming that the Bidder is in fact the Authorized Agent, from the manufacturer it claims to represent. The letter must be an original, under the letterhead of the prime manufacturer. The Bidder will be required to submit the original letter within five (5) calendar days from date of written request. Failure to submit the letter of authorization within the required time frame will result in the bid being declared non-responsive.

Bidder Name (printed)

Manufacturer Name(s)

2.6 Distribution by a Third Party

If the Bidder has an agreement(s) in place with a Third Party Distributor(s) (e.g. a logistics company) with whom the Identified Users may place orders for the products contained in any resulting contract, please indicate the following for each distributor:

- (a) the name of the distributor;
- (b) the complete address including postal code;
- (c) name of local contact and local telephone/facsimile numbers;
- (d) the minimum order per call up required by the distributor;

Name: _____

Address: _____

Telephone No.: _____

E-mail address: _____

Minimum order: _____

Who would be responsible for:

Accepting Orders: Bidder ____ Distributor ____ Either ____

Invoicing: Bidder ____ Distributor ____ Either ____

Receipt of Payment: Bidder ____ Distributor ____ Either ____

2.7 Disclosure of Information - Federal Government Quantities and Pharmaceutical Prime Vendor Standing Offer Holder

Identified Users procure most of their pharmaceutical supplies through a Pharmaceutical Prime Vendor Standing Offer (PPVSO). At the present time, there is a National Master Standing Offer (NMSO) with McKesson Canada to provide this service (Standing Offer E60PH-16PVSO/001/PH).

The Bidder must in the event of a resulting Contract agree and consent to the disclosure of its Contract unit prices to McKesson Canada, or to another PPVSO holder as may be necessitated by a change in current arrangements by Canada. The unit prices are strictly for the use by McKesson Canada (or by another PPVSO Holder) in fulfilling its requirements under the NMSO with the Identified Users. The Bidder further agrees that it will have no right to claim against Canada or the Identified Users in relation to such disclosure.

The Bidder agrees to appoint the Pharmaceutical Prime Vendor, or another PPVSO holder as may be the case, as an Authorized Agent for the purposes of:

- (i) receiving and fulfilling orders under the Standing Offer, and
- (ii) receiving payment.

Confirm your agreement: YES _____ NO _____

PART 3 - BID PREPARATION INSTRUCTIONS

3.1 Bid Preparation Instructions

- (a) If the Bidder chooses to submit its bid electronically, Canada requests that the Bidder submits its bid in accordance with section 8 of the 2003 standard instructions. Bidders must provide their bid in a single transmission. The epost Connect service has the capacity to receive multiple documents, up to 1GB per individual attachment.

The bid must be gathered per section and separated as follows:

- (i) Section I: Technical Bid
 - (ii) Section II: Financial Bid
 - (iii) Section III: Certifications
 - (iv) Section IV: Additional Information
- (b) If the Bidder chooses to submit its bid in hard copies, Canada requests that the Bidder submits its bid in separately bound sections as follows:
- (i) Section I: Technical Bid - 1 hard copy
 - (ii) Section II: Financial Bid - 1 hard copy
 - (iii) Section III: Certifications - 1 hard copy
- (c) If the Bidder is simultaneously providing copies of its bid using multiple acceptable delivery methods, and if there is a discrepancy between the wording of any of these copies and the electronic copy provided through epost Connect service, the wording of the electronic copy provided through epost Connect service will have priority over the wording of the other copies.
- (d) Prices must appear in the financial bid only. No prices must be indicated in any other section of the bid.
- (e) Canada requests that bidders follow the format instructions described below in the preparation of hard copy of their bid:
- (i) use 8.5 x 11 inch (216 mm x 279 mm) paper;
 - (ii) use a numbering system that corresponds to the bid solicitation.
- (f) In April 2006, Canada issued a policy directing federal departments and agencies to take the necessary steps to incorporate environmental considerations into the procurement process [Policy on Green Procurement](https://www.tbs-sct.gc.ca/pol/doc-eng.aspx?id=32573) (<https://www.tbs-sct.gc.ca/pol/doc-eng.aspx?id=32573>). To assist Canada in reaching its objectives, bidders should:
- (i) use 8.5 x 11 inch (216 mm x 279 mm) paper containing fibre certified as originating from a sustainably-managed forest and containing minimum 30% recycled content; and
 - (ii) use an environmentally-preferable format including black and white printing instead of colour printing, printing double sided/duplex, using staples or clips instead of cerlox, duotangs or binders.

3.2 Section I: Technical Bid

- (a) In their technical bid, Bidders should explain and demonstrate how they propose to meet the requirements and how they will carry out the Work.
- (b) For each drug proposed, the Bidder must provide:
 - (i) Drug Identification Number (DIN); or
 - (ii) Evidence that the Bidder has submitted a duly completed New Drug Submission to Health Canada, Biologics and Genetic Therapies Directorate (BGTD), no later than the closing date of this RFP and that BGTD has accepted the submission for review. A copy of the application and proof of acceptance of the submission for review by BGTD must be included.
- (c) The bidder is required to provide full details on its policy for exchanges/credits for returned merchandise, including the return of expired or damaged products, and the return of pharmaceuticals for destruction
- (d) **Bid Submission Form:** Bidders are requested to include the Bid Submission Form – Form 1 with their bids. It provides a common form in which bidders can provide information required for evaluation and contract award, such as a contact name and the Bidder's Procurement Business Number, etc. Using the form to provide this information is not mandatory, but it is recommended. If Canada determines that the information required by the Bid Submission Form is incomplete or requires correction, Canada will provide the Bidder with an opportunity to do so.

3.3 Section II: Financial Bid

- (a) Bidders must submit their financial bid in accordance with the Basis of Payment.
- (b) The quantities provided in Annex A-1 are only an approximation of requirements given in good faith and do not represent any firm commitment by Canada. The quantities specified herein are subject to change prior to Contract award. Each Identified User reserves the right to alter quantities or to withdraw from participation for any given item. A quantity change for an item which represents a significant change in the Requirement may result in a decision to re-tender that item.
- (c) Bidders are to note the unit of measure (U of M) requested for each item and submit their prices accordingly.
- (d) Where the U of M used is per tablet or capsule, Bidders must submit one price per single tablet or capsule.
- (e) Where the U of M used is a bottle, vial or tube, Bidders must submit one price per single bottle, vial or tube in accordance with the item description in the spreadsheet in Annex A-1.
- (f) The Bidder should make every effort to quote on the format size indicated in the item description for bottles, tubes and jars. However, if the Bidder cannot supply the format requested, the Bidder is requested to quote the closest format size available. The Bidder must indicate which format size is being quoted with a note in the "Format Sizes Available" column of the spreadsheet. If necessary, pricing for these items will be evaluated based on one millilitre, one gram, etc.

3.3.1 Electronic Payment of Invoices

If you are willing to accept payment of invoices by Electronic Payment Instruments, complete Annex "H" Electronic Payment Instruments, to identify which ones are accepted.

If Annex "H" Electronic Payment Instruments is not completed, it will be considered as if Electronic Payment Instruments are not being accepted for payment of invoices.

Acceptance of Electronic Payment Instruments will not be considered as an evaluation criterion.

3.3.2 SACC Manual Clauses

- (a) C3011T (2013-11-06) - Exchange Rate Fluctuation
- (b) A9033T (2012-07-16) - Financial Capability

3.4 Section III: Certifications

Bidders must submit the certifications and additional information required under Part 5.

PART 4 - EVALUATION PROCEDURES AND BASIS OF SELECTION

4.1 Evaluation Procedures

- (a) Bids will be assessed in accordance with the entire requirement of the bid solicitation including the technical and financial evaluation criteria.
- (b) An evaluation team composed of representatives of Canada will evaluate the bids.
- (c) Canada will use the Phased Bid Compliance Process described below.

4.1.1 Phased Bid Compliance Process

4.1.1.1 General

- (a) Canada is conducting the PBCP described below for this requirement.
- (b) Notwithstanding any review by Canada at Phase I or II of the PBCP, Bidders are and will remain solely responsible for the accuracy, consistency and completeness of their Bids and Canada does not undertake, by reason of this review, any obligations or responsibility for identifying any or all errors or omissions in Bids or in responses by a Bidder to any communication from Canada.

THE BIDDER ACKNOWLEDGES THAT THE REVIEWS IN PHASE I AND II OF THIS PBCP ARE PRELIMINARY AND DO NOT PRECLUDE A FINDING IN PHASE III THAT THE BID IS NON-RESPONSIVE, EVEN FOR MANDATORY

REQUIREMENTS WHICH WERE SUBJECT TO REVIEW IN PHASE I OR II AND NOTWITHSTANDING THAT THE BID HAD BEEN FOUND RESPONSIVE IN SUCH EARLIER

PHASE. CANADA MAY DEEM A BID TO BE NON-RESPONSIVE TO A MANDATORY REQUIREMENT AT ANY PHASE.

THE BIDDER ALSO ACKNOWLEDGES THAT ITS RESPONSE TO A NOTICE OR A COMPLIANCE ASSESSMENT REPORT (CAR) (EACH DEFINED BELOW) IN PHASE I OR II MAY NOT BE SUCCESSFUL IN RENDERING ITS BID RESPONSIVE TO THE MANDATORY REQUIREMENTS THAT ARE THE SUBJECT OF THE NOTICE OR CAR, AND MAY RENDER ITS BID NON-RESPONSIVE TO OTHER MANDATORY REQUIREMENTS.

- (c) Canada may, in its discretion, request and accept at any time from a Bidder and consider as part of the Bid, any information to correct errors or deficiencies in the Bid that are clerical or administrative, such as, without limitation, failure to sign the Bid or any part or to checkmark a box in a form, or other failure of format or form or failure to acknowledge; failure to provide a procurement business number or contact information such as names, addresses and telephone numbers; inadvertent errors in numbers or calculations that do not change the amount the Bidder has specified as the price or of any component thereof that is subject to evaluation. This shall not limit Canada's right to request or accept any information after the bid solicitation closing in circumstances where the bid solicitation expressly provides for this right. The Bidder will have the time period specified in writing by Canada to provide the necessary documentation. Failure to meet this deadline will result in the Bid being declared non-responsive.
- (d) The PBCP does not limit Canada's rights under Standard Acquisition Clauses and Conditions (SACC) 2003 (2018-05-22) Standard Instructions – Goods or Services – Competitive Requirements nor Canada's right to request or accept any information during the solicitation period or after bid solicitation closing in circumstances where the bid solicitation expressly provides for this right, or in the circumstances described in subsection (c).
- (e) Canada will send any Notice or CAR by any method Canada chooses, in its absolute discretion. The Bidder must submit its response by the method stipulated in the Notice or CAR. Responses are deemed to be received by Canada at the date and time they are delivered to Canada by the method and at the address specified in the Notice or CAR. An email response permitted by the Notice or CAR is deemed received by Canada on the date and time it is received in Canada's email inbox at Canada's email address specified in the Notice or CAR. A Notice or CAR sent by Canada to the Bidder at any address provided by the Bidder in or pursuant to the Bid is deemed received by the Bidder on the date it is sent by Canada. Canada is not responsible for late receipt by Canada of a response, however caused.

4.1.1.2 Phase I: Financial Bid

- (a) After the closing date and time of this bid solicitation, Canada will examine the Bid to determine whether it includes a Financial Bid and whether any Financial Bid includes all information required by the solicitation. Canada's review in Phase I will be limited to identifying whether any information that is required under the bid solicitation to be included in the Financial Bid is missing from the Financial Bid. This review will not assess whether the Financial Bid meets any standard or is responsive to all solicitation requirements.
- (b) Canada's review in Phase I will be performed by officials of the Department of Public Works and Government Services.
- (c) If Canada determines, in its absolute discretion that there is no Financial Bid or that the Financial Bid is missing all of the information required by the bid solicitation to be included in the Financial Bid, then the Bid will be considered non-responsive and will be given no further consideration.
- (d) For Bids other than those described in c), Canada will send a written notice to the Bidder

("Notice") identifying where the Financial Bid is missing information. A Bidder, whose Financial Bid has been found responsive to the requirements that are reviewed at Phase I, will not receive a Notice. Such Bidders shall not be entitled to submit any additional information in respect of their Financial Bid.

- (e) The Bidders who have been sent a Notice shall have the time period specified in the Notice (the "Remedy Period") to remedy the matters identified in the Notice by providing to Canada, in writing, additional information or clarification in response to the Notice. Responses received after the end of the Remedy Period will not be considered by Canada, except in circumstances and on terms expressly provided for in the Notice.
- (f) In its response to the Notice, the Bidder will be entitled to remedy only that part of its Financial Bid which is identified in the Notice. For instance, where the Notice states that a required line item has been left blank, only the missing information may be added to the Financial Bid, except that, in those instances where the addition of such information will necessarily result in a change to other calculations previously submitted in its Financial Bid, (for example, the calculation to determine a total price), such necessary adjustments shall be identified by the Bidder and only these adjustments shall be made. All submitted information must comply with the requirements of this solicitation.
- (g) Any other changes to the Financial Bid submitted by the Bidder will be considered to be new information and will be disregarded. There will be no change permitted to any other Section of the Bidder's Bid. Information submitted in accordance with the requirements of this solicitation in response to the Notice will replace, in full, **only** that part of the original Financial Bid as is permitted above, and will be used for the remainder of the bid evaluation process.
- (h) Canada will determine whether the Financial Bid is responsive to the requirements reviewed at Phase I, considering such additional information or clarification as may have been provided by the Bidder in accordance with this Section. If the Financial Bid is not found responsive for the requirements reviewed at Phase I to the satisfaction of Canada, then the Bid shall be considered non-responsive and will receive no further consideration.
- (i) Only Bids found responsive to the requirements reviewed in Phase I to the satisfaction of Canada, will receive a Phase II review.

4.1.1.3 Phase II: Technical Bid

- (a) Canada's review at Phase II will be limited to a review of the Technical Bid to identify any instances where the Bidder has failed to meet any Eligible Mandatory Criterion. This review will not assess whether the Technical Bid meets any standard or is responsive to all solicitation requirements. Eligible Mandatory Criteria are all mandatory technical criteria that are identified in this solicitation as being subject to the PBCP. Mandatory technical criteria that are not identified in the solicitation as being subject to the PBCP, will not be evaluated until Phase III.
- (b) Canada will send a written notice to the Bidder (Compliance Assessment Report or "CAR") identifying any Eligible Mandatory Criteria that the Bid has failed to meet. A Bidder whose Bid has been found responsive to the requirements that are reviewed at Phase II will receive a CAR that states that its Bid has been found responsive to the requirements reviewed at Phase II. Such Bidder shall not be entitled to submit any response to the CAR.
- (c) A Bidder shall have the period specified in the CAR (the "Remedy Period") to remedy the

failure to meet any Eligible Mandatory Criterion identified in the CAR by providing to Canada in writing additional or different information or clarification in response to the CAR. Responses received after the end of the Remedy Period will not be considered by Canada, except in circumstances and on terms expressly provided for in the CAR.

- (d) The Bidder's response must address only the Eligible Mandatory Criteria listed in the CAR as not having been achieved, and must include only such information as is necessary to achieve such compliance. Any additional information provided by the Bidder which is not necessary to achieve such compliance will not be considered by Canada, except that, in those instances where such a response to the Eligible Mandatory Criteria specified in the CAR will necessarily result in a consequential change to other parts of the Bid, the Bidder shall identify such additional changes, provided that its response must not include any change to the Financial Bid.
- (e) The Bidder's response to the CAR should identify in each case the Eligible Mandatory Criterion in the CAR to which it is responding, including identifying in the corresponding section of the original Bid, the wording of the proposed change to that section, and the wording and location in the Bid of any other consequential changes that necessarily result from such change. In respect of any such consequential change, the Bidder must include a rationale explaining why such consequential change is a necessary result of the change proposed to meet the Eligible Mandatory Criterion. It is not up to Canada to revise the Bidder's Bid, and failure of the Bidder to do so in accordance with this subparagraph is at the Bidder's own risk. All submitted information must comply with the requirements of this solicitation.
- (f) Any changes to the Bid submitted by the Bidder other than as permitted in this solicitation, will be considered to be new information and will be disregarded. Information submitted in accordance with the requirements of this solicitation in response to the CAR will replace, in full, **only** that part of the original Bid as is permitted in this Section.
- (g) Additional or different information submitted during Phase II permitted by this section will be considered as included in the Bid, but will be considered by Canada in the evaluation of the Bid at Phase II only for the purpose of determining whether the Bid meets the Eligible Mandatory Criteria. It will not be used at any Phase of the evaluation to increase or decrease any score that the original Bid would achieve without the benefit of such additional or different information. For instance, an Eligible Mandatory Criterion that requires a mandatory minimum number of points to achieve compliance will be assessed at Phase II to determine whether such mandatory minimum score would be achieved with such additional or different information submitted by the Bidder in response to the CAR. If so, the Bid will be considered responsive in respect of such Eligible Mandatory Criterion, and the additional or different information submitted by the Bidder shall bind the Bidder as part of its Bid, but the Bidder's original score, which was less than the mandatory minimum for such Eligible Mandatory Criterion, will not change, and it will be that original score that is used to calculate any score for the Bid.
- (h) Canada will determine whether the Bid is responsive for the requirements reviewed at Phase II, considering such additional or different information or clarification as may have been provided by the Bidder in accordance with this Section. If the Bid is not found responsive for the requirements reviewed at Phase II to the satisfaction of Canada, then the Bid shall be considered non-responsive and will receive no further consideration.

- (i) Only Bids found responsive to the requirements reviewed in Phase II to the satisfaction of Canada, will receive a Phase III evaluation.

4.1.1.4 Phase III: Final Evaluation of the Bid

- (a) In Phase III, Canada will complete the evaluation of all Bids found responsive to the requirements reviewed at Phase II. Bids will be assessed in accordance with the entire requirement of the bid solicitation including the technical and financial evaluation criteria.
- (b) A Bid is non-responsive and will receive no further consideration if it does not meet all mandatory evaluation criteria of the solicitation.

4.1.2 Technical Evaluation - Mandatory Technical Criteria

As specified under the Mandatory Technical in Annex E.

The Phased Bid Compliance Process will apply to all mandatory technical criteria.

4.1.3 Financial Evaluation

As specified under the Financial Offer in Annex F.

4.2 Basis of Selection

- (a) A bid must comply with the requirements of the bid solicitation and meet all mandatory evaluation criteria to be declared responsive.
- (b) If there are two or more bids with identical lowest evaluated prices, the names of all Bidders with identical lowest bid prices will be placed in a hat and the winner will be the first name drawn from it. All Bidders with the lowest bid price will be invited to witness the event.
- (c) Recommendation for contract award will be based on the lowest responsive price per item as indicated at Annex A-1. Multiple contracts may be awarded from this solicitation.

PART 5 - CERTIFICATIONS AND ADDITIONAL INFORMATION

Bidders must provide the required certifications and additional information to be awarded a contract.

The certifications provided by Bidders to Canada are subject to verification by Canada at all times. Unless specified otherwise, Canada will declare a bid non-responsive, or will declare a contractor in default if any certification made by the Bidder is found to be untrue whether made knowingly or unknowingly, during the bid evaluation period or during the contract period.

The Contracting Authority will have the right to ask for additional information to verify the bidder's certification. Failure to comply and to cooperate with any request or requirement imposed by the Contracting Authority will render the bid non-responsive or constitute a default under the Contract.

5.1 Certifications Required with the Bid

Bidders must submit the following duly completed certifications as part of their bid.

5.1.1 Integrity Provisions - Declaration of Convicted Offences

In accordance with the Integrity Provisions of the Standard Instructions, all bidders must provide with their bid, if applicable, the declaration form available on the Forms for the Integrity Regime website (<http://www.tpsgc-pwgsc.gc.ca/ci-if/declaration-eng.html>) to be given further consideration in the procurement process.

5.2 Certifications Precedent to Contract Award and Additional Information

The certifications and additional information listed below should be submitted with the bid, but may be submitted afterwards. If any of these required certifications or additional information is not completed and submitted as requested, the Contracting Authority will inform the Bidder of a time frame within which to provide the information. Failure to provide the certifications or the additional information listed below within the time frame provided will render the bid non-responsive.

5.2.1 Integrity Provisions – Required Documentation

In accordance with the Integrity Provisions of the Standard Instructions, all bidders must provide with their bid, **if applicable**, the declaration form available on the Forms for the Integrity Regime website (<http://www.tpsgc-pwgsc.gc.ca/ci-if/declaration-eng.html>), to be given further consideration in the procurement process.

5.2.2 Federal Contractors Program for Employment Equity - Bid Certification

- (a) By submitting a bid, the Bidder certifies that the Bidder, and any of the Bidder's members if the Bidder is a Joint Venture, is not named on the Federal Contractors Program (FCP) for employment equity "FCP Limited Eligibility to Bid" list available at the bottom of the page of the Employment and Social Development Canada (ESDC) - Labour's website (<https://www.canada.ca/en/employment-social-development/programs/employment-equity/federal-contractor-program.html#>)
- (b) Canada will have the right to declare a bid non-responsive if the Bidder, or any member of the Bidder if the Bidder is a Joint Venture, appears on the "FCP Limited Eligibility to Bid" list at the time of contract award.
- (c) Canada will also have the right to terminate the Contract for default if a Contractor, or any member of the Contractor if the Contractor is a Joint Venture, appears on the "FCP Limited Eligibility to Bid" (<https://www.canada.ca/en/employment-social-development/programs/employment-equity/federal-contractor-program.html#s4>) list during the period of the Contract.
- (d) The Bidder must provide the Contracting Authority with a completed annex titled Federal Contractors Program for Employment Equity - Certification (Annex D to Part 5), before contract award. If the Bidder is a Joint Venture, the Bidder must provide the Contracting Authority with a completed annex Federal Contractors Program for Employment Equity - Certification, for each member of the Joint Venture.

PART 6 - RESULTING CONTRACT CLAUSES

6.1 Security Requirement

There is no security requirement applicable to this Contract.

6.2 Requirement

The Contractor must provide the items detailed under the Requirement at Annex A-1 to Identified Users as listed in Annex B.

6.3 Standard Clauses and Conditions

All clauses and conditions identified in the Contract by number, date and title are set out in Standard Acquisition Clauses and Conditions Manual (<http://buyandsell.gc.ca/policy-and-guidelines/standard-acquisition-clauses-and-conditions-manual>) issued by Public Works and Government Services Canada.

6.3.1 General Conditions

2010A (2018-06-21) General Conditions - Goods - Medium Complexity, apply to and form part of the Contract.

6.3.2 Warranty - Amendment to General Conditions 2010A

Section 09, paragraph 1, of General Conditions 2010A, which forms part of the Contract will not apply to Work with a specified expiry date. The following paragraph replaces section 9, paragraph 1, General Conditions 2010A for Work with a specified expiry date:

- (a) Despite inspection and acceptance of the Work by or on behalf of Canada and without restricting any other provision of the Contract or any condition, warranty or provision implied or imposed by law, the Contractor warrants that the Work conforms to the specifications until the expiration date required by the Requirement. The Contractor must, upon the request of Canada, replace at its own expense including costs of returns and delivery of replacement Work as soon as possible any supplies that fail to conform or that deteriorates prior to the expiration date required by the Requirement.
- (b) If full replacement is not available in a timeframe acceptable to Canada, then Canada may, in addition to and without prejudice to any other remedy available, choose from one of the following options for the quantity and Contract value of the Work affected:
 - (i) Full and immediate reimbursement;
 - (ii) Equivalent full credit against future purchases under the Contract; or
 - (iii) Partial replacement and partial reimbursement or partial credit.

6.4 Term of Contract

6.4.1 Period of Contract

The period for placing orders and rendering services against the Contract will from July 1, 2019 up to and including June 30, 2020.

6.4.2 Option to Extend the Contract

- (a) The Contractor grants to Canada the irrevocable option to extend the term of the Contract by up to two (2) additional one (1) year period(s) (from July 1, 2020 to June 30, 2021 and July 1, 2021 to June 30, 2022) under the same conditions. The Contractor agrees that, during the extended period of the Contract, it will be paid in accordance with the applicable provisions as set out in the Basis of Payment.
- (b) Canada may exercise this option at any time by sending a written notice to the Contractor at least 30 calendar days prior the expiry date of the contract. The option may only be exercised by the Contracting Authority, and will be evidenced for administrative purposes only, through a contract amendment.

6.4.3 Option - Add Identified User

Subject to the mutual agreement of the Contractor and Canada, additional Identified Users may be added to the Contract at a price not to exceed the Contract price and subject to the same conditions

6.5 Authorities

6.5.1 Contracting Authority

- (a) The Contracting Authority for this Contract is:

Suzanne Bissonnette
Supply Specialist
Public Works and Government Services Canada
Drugs, Vaccines & Biologics
10 Wellington Street, 5th Floor
Gatineau, Quebec K1A 0S5
Building Terrasses de la Chaudière

Telephone: 819-360-4895
Email address: suzanne.bissonnette@pwgsc.gc.ca

- (b) The Contracting Authority is responsible for the management of the Contract and the Contracting Authority must authorize any changes to the Contract in writing. The Contractor must not perform work in excess of or outside the scope of the Contract based on verbal or written requests or instructions from anybody other than the Contracting Authority.

6.5.2 Identified Users

- (a) The list of Identified Users is provided in Annex B.
- (b) The Identified Users are the representatives of the department, agency, province or territory for whom the Work is being carried out under the Contract. The Identified Users have no authority to authorize changes to the scope of the Work. Changes to the scope of the Work can only be made through a contract amendment issued by the Contracting Authority.
- (c) The Contractor understands and agrees that each Identified User may specify multiple authorized representatives and destination points and may change and/or add to the authorized representatives and destinations specified on Annex B.

6.5.3 Other Users

Other users include other Federal Government Departments and Agencies and/or other Provinces / Territories not currently included on Annex B.

6.5.4 Canada and Public Works and Government Services as Agent

- (a) The Contractor acknowledges that Canada is acting as an agent for Identified Users. Canada will only be funding and paying for Orders placed on behalf of a Federal Government Department or Agency.
- (b) Orders placed by or on behalf of a non-Federal Government Department or Agency Identified User under the Contract are the responsibility of the Identified User for whom or by whom the Order is placed. To the extent that the Contract involves orders placed by Canada on behalf of a non-Federal Government Department or Agency Identified User, Canada is acting as an agent for the Identified User only and the Identified User is solely liable and responsible for funding and payment of those orders.
- (c) The Contractor acknowledges and agrees that, unless otherwise specified, Canada is not liable under the Contract to the extent that it involves Orders placed on or on behalf of a non-Federal Government Department or Agency Identified User, and the Contractor agrees that it must not make any claim or take any proceeding against Canada for any loss, damages, or non-payment in any way related to or arising out of such Orders.

6.5.5 Contractor Representative

NOTE TO BIDDER: Please include the requested information on "FORM 1 - BID SUBMISSION".

- (a) General enquiries:

Name:
Telephone No.:
Facsimile No.:
E-mail address:

- (b) Delivery follow-up:

Name:
Telephone No.:
Facsimile No.:
E-mail address:

6.6 Authorized Agents

The Third Party Distributor(s) listed herein have been appointed by the Contractor as an Authorized Agent(s) for the purpose of:

- (i) receiving and fulfilling orders under the contract; and
- (ii) for the purpose of receiving payment.

Authorized Agent(s):

Receipt by the Authorized Agent of payment for any order filled by that Authorized Agent will be deemed to be receipt by the Contractor of such payment. This arrangement does not remove the Contractor from any of their responsibilities under this Contract. The Contractor agrees and understands that it will be solely responsible for ensuring that all Authorized Agents are aware of and comply with the terms and conditions of the contract. The Contractor must provide a complete copy of the Contract to each Authorized Agent for reference.

The Contractor is responsible for delivery in the event of default by the Authorized Agent(s) for those products only that are normally offered by the Contractor.

The Contractor agrees that if the Authorized Agent defaults on one or more items, the order cannot be terminated in whole, but only for those portions relating to goods or services specified in the particular Contract to which the default relates and only after the Contractor has been provided with a reasonable opportunity to remedy the default. If during the contract period there is a change in the list of Agents as initially indicated in the contract, the Contractor must immediately inform the PWGSC Contracting Authority listed herein, in writing, of this change.

6.6.1 Disclosure of Information - Contracts (Multiple)

The Contractor agrees and accepts that its Agent(s) listed on this contract may represent the holder of a contract other than itself. The Contractor further agrees and accepts that its prices, along with those prices offered by those other Contractors, will appear on the multiple order form, thereby making the prices specified public information.

6.6.2. Disclosure of Information - Federal Government Pharmaceutical Prime Vendor Standing Offer Holder

Identified Users procure most of their pharmaceutical supplies through a Pharmaceutical Prime Vendor Standing Offer (PPVSO). At the present time, there is a National Master Standing Offer (NMSO) with McKesson Canada to provide this service (Standing Offer E60PH-16PVSO/001/PH). The Contractor agrees and consents to the disclosure of its Contract unit prices to McKesson Canada, or to another PPVSO holder as may be necessitated by a change in current arrangements by Canada. The unit prices are strictly for the use by McKesson Canada (or by another PPVSO Holder) in fulfilling its requirements under the NMSO with the Identified Users. The Contractor agrees to appoint the Pharmaceutical Prime Vendor, or another PPVSO holder as may be the case, as an Authorized Agent for the purposes of:

- (i) receiving and fulfilling orders under the Standing Offer, and
- (ii) receiving payment.

In order to facilitate this process, **within 5 working days** of receiving the Contract award, and/or any subsequent contract amendments, the Contractor must supply a copy of the Contract pricing to:

To be provided at contract award

6.7 Ordering

6.7.1 Order against Contract

- (a) The Work to be performed under the Contract will be on an "as and when requested basis" using an Order against Contract ("Order").
- (b) **Process for Issuing an Order:** If a requirement is identified, an Order will be prepared by the Identified User and sent to the Contractor by letter, by e-mail, or by telephone, or any other means agreed to by the parties and evidenced in writing.
- (c) **Contents of an Order:** The Order must contain the following information, if applicable:
 - (i) An order number;
 - (ii) price, quantity and description of goods being ordered;
 - (iii) delivery location;
 - (iv) invoicing address; and
 - (v) any other constraints that might affect the work.
- (d) **Delivery:** Unless otherwise indicated in the Order, delivery must be made within seven (7) calendar days from receipt of an Order.
- (e) **Charges for Work under an Order:** The Contractor must not charge the Identified User anything more than the price set out in the Order unless the Identified User has issued an Order amendment authorizing the increased expenditure. The Identified User will not pay the Contractor for any design changes, modifications or interpretations of the Work unless they have been approved, in writing, by the Contracting Authority before being incorporated into the Work.
- (f) Each Identified User may change and/or add to the destinations specified in Annex "C".

6.7.2 Minimum Work Guarantee - All the Work

- (a) In this clause,

"Maximum Contract Value" means the amount specified in the "Limitation of Expenditure" clause set out in the Contract; and

"Minimum Contract Value" means \$ to be inserted at contract award
- (b) Canada's obligation under the Contract is to request Work in the amount of the Minimum Contract Value or, at Canada's option, to pay the Contractor at the end of the Contract in accordance with paragraph (c). In consideration of such obligation, the Contractor agrees to stand in readiness throughout the Contract period to perform the Work described in the Contract. Canada's maximum liability for work performed under the Contract must not exceed the Maximum Contract Value, unless an increase is authorized in writing by the Contracting Authority.
- (c) In the event that Canada does not request Work in the amount of the Minimum Contract Value during the period of the Contract, Canada must pay the Contractor the difference between the Minimum Contract Value and the total cost of the Work requested.
- (d) Canada will have no obligation to the Contractor under this clause if Canada terminates the Contract in whole or in part for default.

6.8 Packaging

Packaging is to be in accordance with good commercial standards to ensure safe arrival at destination. In addition to the Contract Requirement, the Contractor must ensure that all goods are properly labeled and packaged in compliance with the Biologics and Genetic Therapies Directorate (BGTD) Regulations.

6.8.1 Shipping Instructions

Goods must be consigned to the destinations specified in the order and delivered DDP Delivered Duty Paid (per order/call up document), Incoterms 2000 for shipments from a commercial contractor.

6.8.2 Maintenance of the Cold Chain During Transportation

Throughout the shipping process, the product must remain in temperature controlled and monitored conditions in accordance with the manufacturer's recommended storage conditions and/or as described within the product monograph.

6.8.3 Shipment of Hazardous Materials

The Contractor must label and ship goods falling within the Hazardous Products Act, R.S.C. 1985, c. H-3 and regulation(s) in accordance with the said Act and regulation(s) accompanied by the required material safety data sheet(s) completed in either English or French. The label must clearly identify the contents of the hazardous material and the material safety data sheet must explain what those hazards are.

6.9 Payment

6.9.1 Basis of Payment - Firm Unit Price(s)

In consideration of the Contractor satisfactorily completing all of its obligations under the Contract, the Contractor will be paid a firm unit price as specified in Annex A-1. Customs duties are included and Applicable Taxes are extra.

6.9.2 Limitation of Expenditure - Cumulative Total of all Orders

- (a) Canada's total liability to the Contractor under the Contract for all Orders, inclusive of any revisions, must not exceed the sum of \$to be inserted at contract award. Customs duties are included, and Applicable Taxes are extra.
- (b) No increase in the total liability of Canada will be authorized or paid to the Contractor unless an increase has been approved, in writing, by the Contracting Authority.

6.9.3 Electronic Payment of Invoices *(if applicable, to be inserted at contract award)*

The Contractor accepts to be paid using any of the following Electronic Payment Instrument(s):

- (a) Visa Acquisition Card;
- (b) MasterCard Acquisition Card;
- (c) Direct Deposit (Domestic and International);
- (d) Electronic Data Interchange (EDI);
- (e) Wire Transfer (International Only);
- (f) Large Value Transfer System (LVTS) (Over \$25M)

6.9.4 SACC Manual Clauses

- (a) H1001C (2008-05-12), Multiple Payments

6.10 Invoicing Instructions

- (a) The Contractor must submit invoices in accordance with the section entitled "Invoice Submission" of the general conditions. Invoices cannot be submitted until all work identified in the invoice is completed.
- (b) The original and one copy of all invoices are to be forwarded to the Identified User specified on the Order for certification and payment.

6.11 Product Recall or Withdrawal

- (a) In the event of a recall or a withdrawal of Work, the Contractor must notify the Contracting Authority and all Identified Users who have been delivered the recalled or withdrawn Work and must collect and destroy the delivered, recalled, or withdrawn Work at their own cost.
- (b) The Contractor must, upon the request of Canada or an Identified User, replace as soon as possible any recalled or withdrawn Work at their own cost.
- (c) If full replacement is not available in a timeframe acceptable to Canada or an Identified User, then Canada or the Identified User may, in addition to and without prejudice to any other remedy available, choose from one of the following options for the quantity and Contract value of the Work affected:
 - (i) Full and immediate reimbursement;
 - (ii) Equivalent full credit against future purchases under the Contract; or
 - (iii) Partial replacement and partial immediate reimbursement or partial credit under the Contract.

6.12 Returns

In addition to and without prejudice to any other remedy available, for work:

- (a) Damaged during shipment from Contractor, the Contractor must provide full credit or replacement or refund for all returned Work where Contractor was contacted within 5 days of delivery to and acceptance by the Identified User. Damaged Work will be returned FCA Free Carrier (Identified user) Incoterms 2000 to the address specified below. The Contractor is responsible for shipping costs.
- (b) Contractor's Return Facilities:

NOTE TO BIDDER: Please include the requested information on "FORM 1 - BID SUBMISSION".

Address:
Contact Name:
Telephone:
Facsimile:
Email:

6.13 Notice of Anticipated Shortage

- (a) The Contractor must notify the Contracting Authority when it becomes aware of a potential problem, delay, or event that may lead to a shortage of any of the quantities listed in Annex A-1. Such notice must include a description of the nature of the problem or delay or event, the anticipated impact on the requirements of the Contract, the steps being taken by the Contractor to rectify the situation or to minimize the impact on this Contract, and the expected date by which the shortage will be fully corrected.
- (b) For the purpose of this clause "shortage" is defined as the inability to meet an Order in full or the failure to maintain the minimum stockpile, if applicable.

6.14 Inability to Supply

- (a) In the event that the Contractor is unable to supply the Work in accordance with the terms and conditions of the Contract, whether as the result of product discontinuation or for any other reason, the Contractor will provide a substitute product acceptable to the Identified User at a price no greater than firm unit price specified in Annex A-1.
- (b) Should the Identified User be required to purchase the Work from an alternate source at a higher price, the Contractor must reimburse the Identified User for the difference between the price paid to the alternate source and the firm unit price specified in Annex A-1
- (c) Should the Identified User be required to purchase the Work from an alternate source, Canada reserves the right to adjust the final total estimated quantity in the Contract.

6.15 Reporting

6.15.1 Periodic Usage Reports:

The Contractor must provide a report for all purchases under the Contract. The report must be submitted in an electronic format to the Contracting Authority and must summarize the following:

- (a) all purchases by Identified Users listed in Annex B;
- (b) The Contractor must provide this data in accordance with the reporting requirements detailed in Annex C. If some data is not available, the reason must be indicated. If no there are purchases during a given period, the Contractor must still provide a "NIL" report.
- (c) The data must be submitted in electronic format to the Contracting Authority on a biannual basis for the duration of the Contract. The reporting periods are defined as follows:
 - (i) July 1 to December 31; and
 - (ii) January 1 to June 30.

The data must be submitted to the Contract Authority no later than 15 calendar days after the end of the reporting period.

6.15.2 Reports - Fiscal Year-End Usage Report - Upon Request

In addition to the reporting requirements above, the Contractor must provide usage report for all purchases by the Identified User listed in Annex "C " for the Federal Government's fiscal year-end.

The Contractor must provide this data in accordance with the reporting requirements detailed in Annex " C ". If some data is not available, the reason must be indicated. If there are no purchases during a given period, the Contractor must still provide a "NIL" report.

The data must be submitted in electronic format on a yearly basis to the Contract Authority.
The fiscal reporting periods are defined as follows:

- (i) 1st year: Contract Award to March 31, 2020;
- (ii) Option year one: April 1, 2020 to March 31, 2021;
- (iii) Option year two: April 1, 2021 to March 31, 2022.

The data must be submitted to the Contract Authority no later than 15 calendar days after the end of the reporting period.

6.16 Certifications

6.16.1 Compliance

Unless specified otherwise, the continuous compliance with the certifications provided by the Contractor in its bid or precedent to contract award, and the ongoing cooperation in providing additional information are conditions of the Contract and failure to comply will constitute the Contractor in default. Certifications are subject to verification by Canada during the entire period of the Contract.

6.17 Federal Contractors Program for Employment Equity - Default by the Contractor

The Contractor understands and agrees that, when an Agreement to Implement Employment Equity (AIEE) exists between the Contractor and Employment and Social Development Canada (ESDC) - Labour, the AIEE must remain valid during the entire period of the Contract. If the AIEE becomes invalid, the name of the Contractor will be added to the "FCP Limited Eligibility to Bid" list. The imposition of such a sanction by ESDC will constitute the Contractor in default as per the terms of the Contract.

6.18 Applicable Laws

The Contract must be interpreted and governed, and the relations between the parties determined, by the laws in force in the province of Ontario.

6.19 Priority of Documents

If there is a discrepancy between the wording of any documents that appear on the list, the wording of the document that first appears on the list has priority over the wording of any document that subsequently appears on the list.

- (a) the Articles of Agreement;
- (b) the general conditions 2010A (2018-06-21) Goods (Medium Complexity);
- (c) Annex A: Statement of Requirement, Pricing & Deliverables;
- (d) Annex B: Identified Users and Delivery Points;
- (e) Annex C: Example of Periodic Report
- (f) Annex D: Return Policy
- (g) Annex E: Technical Mandatory Criteria
- (h) Annex F: Financial Offer
- (i) Annex G: Federal Contractors Program for Employment Equity - Certification
- (j) the Contractor's bid dated_____.

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

6.20 Defence Contract

- (a) The Contract is a defence contract within the meaning of the Defence Production Act, R.S.C. 1985, c. D-1, and must be governed accordingly.
- (b) Title to the Work or to any materials, parts, work-in-process or finished work must belong to Canada free and clear of all claims, liens, attachments, charges or encumbrances. Canada is entitled, at any time, to remove, sell or dispose of the Work or any part of the Work in accordance with section 20 of the Defence Production Act.

6.21 Insurance

SACC Manual Clause G1005C (2016-01-28), Insurance – No Specific Requirement

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

Annex A

STATEMENT OF REQUIREMENT, PRICING & DELIVERABLES

1. Requirement:

To supply pharmaceuticals in accordance with the item descriptions listed in the attached Annex A-1.

2. Price Proposal

All prices must be in Canadian dollars, DDP Delivered Duty Paid (per order/call-up document), transportation charges included. Customs duties are included and Applicable Taxes are extra. Each firm unit price is applicable for all destinations in Canada.

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

Annex A-1

(Please see list of products at the end of the solicitation)

Annex A - 2

Ontario's format requirements

Description	Format required
ACETAMINOPHEN TABLET 325 MG ORAL	Bottle of 1000 tablets
ACETAMINOPHEN TABLET 500 MG ORAL	Bottle of 1000 tablets
ACYCLOVIR OINT. (G) 5% TOPICAL OINTMENT	30G TUBE
AMITRIPTYLINE HCL TABLET 50 MG ORAL	Bottle of 100 tablets
AMLODIPINE BESYLATE TABLET 5 MG ORAL	Bottle of 100 tablets
AMOXICILLIN CAPSULE 250 MG ORAL	Bottle of 100 capsules
AMOXICILLIN CAPSULE 500 MG ORAL	Bottle of 100 capsules
ATORVASTATIN CALCIUM TABLET 10 MG ORAL	Bottle of 90 or 100 tablets
AZITHROMYCIN TABLET 250 MG ORAL	Pack of 6 tablets
BISACODYL TABLET EC (ENTERIC COATED) 5 MG ORAL	Bottle of 100 tablets
BUPROPION HCL TAB ER 24H 150 MG ORAL	Bottle of 90 tablets
BUPROPION HCL TAB ER 24H 300 MG ORAL	Bottle of 90 tablets
BUPROPION HCL TABLET ER 150 MG ORAL	Bottle of 60 tablets
BUSPIRONE HCL TABLET 10 MG ORAL	Bottle of 100 tablets
CEFIXIME TABLET 400 MG ORAL	Box of 10 Tabs
CETIRIZINE HCL TABLET 10 MG ORAL	Bottle of 100 tablets
CITALOPRAM HYDROBROMIDE TABLET 20 MG ORAL	Bottle of 100 tablets
CLINDAMYCIN HCL CAPSULE 300 MG ORAL	Bottle of 100 capsules
CYCLOBENZAPRINE HCL TABLET 10 MG ORAL	Bottle of 100 tablets
DEXTROMETHORPHAN HBR LIQUID 15 MG/5 ML ORAL	Bottle of 250 ML
DIMENHYDRINATE TABLET 50 MG ORAL	Bottle of 100 or 250 tablets
DIPHENHYDRAMINE HCL 25 MG ORAL	Bottle of 100 or 250 tablets/capsules
DIPHENHYDRAMINE HCL 50 MG ORAL	Bottle of 100 tablets/capsules
DIVALPROEX SODIUM TABLET DR 250 MG ORAL	Bottle of 100 tablets
DOXEPIN HCL CAPSULE 50 MG ORAL	Bottle of 100 capsules
DOXYCYCLINE HYCLATE 100 MG ORAL	Bottle of 100 tablets/capsules
DULOXETINE HCL CAPSULE DR 30 MG ORAL	Bottle of 100 capsules
DULOXETINE HCL CAPSULE DR 60 MG ORAL	Bottle of 100 capsules
ESCITALOPRAM OXALATE TABLET 10 MG ORAL	30 tablets
FLUTICASONE PROPIONATE SPRAY SUSP 50 MCG NASAL	120 dose nasal spray
PREGABALIN CAPSULE 150 MG ORAL	Bottle of 100 capsules
PREGABALIN CAPSULE 75 MG ORAL	Bottle of 100 capsules
QUETIAPINE FUMARATE TAB ER 24H 50 MG ORAL	Bottles of 60 or 100 tablets
QUETIAPINE FUMARATE TABLET 100 MG ORAL	Bottle of 100 tablets
QUETIAPINE FUMARATE TABLET 200 MG ORAL	Bottle of 100 tablets

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

QUETIAPINE FUMARATE TABLET 25 MG ORAL	Bottle of 100 tablets
RANITIDINE HCL TABLET 150 MG ORAL	Bottles of 100 tablets
RIFAMPIN CAPSULE 150 MG ORAL	Bottle of 100 capsules
RIFAMPIN CAPSULE 300 MG ORAL	Bottle of 100 capsules
ROSUVASTATIN CALCIUM TABLET 10 MG ORAL	Box of 30 tabs
SALBUTAMOL SULFATE HFA AER AD 100 MCG INHAL	200 dose inhaler
SERTRALINE HCL CAPSULE 100 MG ORAL	Bottle of 100 capsules
SERTRALINE HCL CAPSULE 50 MG ORAL	Bottle of 100 capsules
SITAGLIPTIN PHOSPHATE TABLET 100 MG ORAL	Bottle of 100 tablets
TERBINAFINE HCL CREAM (G) 1% TOPICAL	30G TUBE
TRAZODONE HCL TABLET 100 MG ORAL	Bottle of 100 tablets
TRAZODONE HCL TABLET 50 MG ORAL	Bottle of 100 tablets
VENLAFAXINE HCL CAP ER 24H 150 MG ORAL	Bottle of 100 capsules
VENLAFAXINE HCL CAP ER 24H 75 MG ORAL	Bottle of 100 capsules
ZOPICLONE TABLET 7.5 MG ORAL	Bottle of 100 tablets

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

ANNEX B - IDENTIFIED USERS AND DELIVERY POINTS

Department of National Defence	
Billing Addresses	Delivery Addresses
CANADIAN FORCES HEALTH SERVICES UNIT (PACIFIC) PHARMACY 1200 COLVILLE ROAD VICTORIA, BC V9A 7N2	CANADIAN FORCES HEALTH SERVICES UNIT (PACIFIC) PHARMACY 1200 COLVILLE ROAD VICTORIA, BC V9A 7N2
MEDICAL PROVISION POINT ESQUIMALT C/O CANADIAN FORCES HEALTH SERVICES UNIT (PACIFIC) 1200 COLVILLE ROAD VICTORIA, BC V9A 7N2	MEDICAL PROVISION POINT ESQUIMALT C/O CANADIAN FORCES HEALTH SERVICES UNIT (PACIFIC) 1200 COLVILLE ROAD VICTORIA, BC V9A 7N2
21 CANADIAN FORCES HEALTH SERVICES CENTRE COMOX 19 WING CFB COMOX BUILDING 27 LAZO, BC V0R 2K0	21 CF HEALTH SERVICES CENTRE COMOX 19 WING CFB COMOX BUILDING 27 LAZO, BC V0R 2K0
22 CANADIAN FORCES HEALTH SERVICES CENTRE COLD LAKE 4 WING CFB COLD LAKE BUILDING 69 COLD LAKE, AB T9M 2C6	22 CF HEALTH SERVICES CENTRE COLD LAKE 4 WING CFB COLD LAKE BUILDING 69 COLD LAKE, AB T9M 2C6
1 FIELD AMBULANCE CLINIC PHARMACY CANADIAN FORCES BASE EDMONTON GARRISON BUILDING 162, LANCASTER PARK PO BOX 10500 STATION FORCES EDMONTON, AB T5J 4J5	1 FIELD AMBULANCE CLINIC PHARMACY CANADIAN FORCES BASE EDMONTON GARRISON BUILDING 162, LANCASTER PARK PO BOX 10500 STATION FORCES EDMONTON, AB T5J 4J5
1 FIELD AMBULANCE BRIGADE PHARMACY BUILDING 175 LANCASTER PARK P.O. BOX 9700 STN FORCES EDMONTON, AB T5J 4J5	1 FIELD AMBULANCE BRIGADE PHARMACY BUILDING 175 LANCASTER PARK P.O. BOX 9700 STN FORCES EDMONTON, AB T5J 4J5
1 FIELD AMBULANCE DETACHMENT WAINWRIGHT BUILDING 633 DENWOOD, AB T0B 1B0	1 FIELD AMBULANCE DETACHMENT WAINWRIGHT PHARMACY BUILDING 633 DENWOOD, AB T0B 1B0
CF H SVCS C PHARMACY MAPLE RESOLVE BLDG 633 PERIMETER RD DENWOOD AB T0B 1B0	CF H SVCS C PHCY MAPLE RESOLVE BLDG 633 PERIMETER RD DENWOOD AB T0B 1B0
1 FD AMB DET SUFFIELD PO BOX 6000 STN MAIN MEDICINE HAT AB T1A 8K8	1 FD AMB DET SUFFIELD PO BOX 6000 STN MAIN MEDICINE HAT AB T1A 8K8
23 CF HEALTH SERVICES CENTRE DET MOOSE JAW 15 WING CFB MOOSE JAW BUILDING 143 NATO DRIVE PO BOX 5000 MOOSE JAW, SK S6H 7Z8	23 CF HEALTH SERVICES CENTRE DET MOOSE JAW 15 WING CFB MOOSE JAW BUILDING 143 NATO DRIVE PO BOX 5000 MOOSE JAW, SK S6H 7Z8
23 CANADIAN FORCES HEALTH SERVICES CENTRE WINNIPEG 17 WING MEDICAL SQN CFB WINNIPEG BUILDING 62 PO BOX 17000 STATION FORCES WINNIPEG, MB R3J 0T0	23 CANADIAN FORCES HEALTH SERVICES CENTRE WINNIPEG 17 WING MEDICAL SQN CFB WINNIPEG BUILDING 62 PO BOX 17000 STATION FORCES WINNIPEG, MB R3J 0T0

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

11 CANADIAN FORCES HEALTH SERVICES CENTRE SHILO CANADIAN FORCES BASE SHILO BUILDING L-158 SHILO, MB R0K 2A0	11 CF HEALATH SERVICES CENTRE SHILO CANADIAN FORCES BASE SHILO BUILDING L-158 SHILO, MB R0K 2A0
TWOVP UMT 11 CF HSVCS C BLDG L158 BOX 5000 ST MAIN SHILO MB R0K 2A0	TWOVP UMT 11 CF HSVCS C BLDG L158 BOX 5000 ST MAIN SHILO MB R0K 2A0
CANADIAN FORCES HEALTH SERVICES CENTER (OTTAWA) PHARMACY 1745 ALTA VISTA DRIVE OTTAWA, ON K1A 0K6	CANADIAN FORCES HEALTH SERVICES CENTER (OTTAWA) PHARMACY 1745 ALTA VISTA DRIVE OTTAWA, ON K1A 0K6
24 CANADIAN FORCES HEALTH SERVICES CENTRE TRENTON 8 WING CFB TRENTON 50 YUKON ST ASTRA, ON K0K 1B0	24 CANADIAN FORCES HEALTH SERVICES CENTRE TRENTON 8 WING CFB TRENTON 50 YUKON ST, BLDG 20 ASTRA, ON K0K 1B0
CMED DET TRENTON 54 PORTAGE AVE BLDG 416 8 WING TRENTON ASTRA ON K0C 3W0	CMED DET TRENTON 54 PORTAGE AVE BLDG 416 8 WING TRENTON ASTRA ON K0C 3W0
24 CANADIAN FORCES HEALTH SERVICES CENTRE DETACHMENT NORTH BAY 22 WING CFB NORTH BAY HORNELL HEIGHTS, ON P0H 1PO	24 CF HEALTH SERVICES CENTRE DET NORTH BAY 95 MANTSON CRES 22 WING CFB NORTH BAY HORNELL HEIGHTS, ON P0H 1PO
33 CANADIAN FORCES HEALTH SERVICES CENTRE KINGSTON CANADIAN FORCES BASE KINGSTON BLDG B62 1 ENTRETIEN AVE PO BOX 17000 STATION FORCES KINGSTON, ON K7K 7B4	33 CANADIAN FORCES HEALTH SERVICES CENTRE KINGSTON CANADIAN FORCES BASE KINGSTON BLDG B62 1 ENTRETIEN AVE PO BOX 17000 STATION FORCES KINGSTON, ON K7K 7B4
32 CANADIAN FORCES HEALTH SERVICES CENTRE TORONTO DENISON ARMOURY 1 YUKON LANE NORTH YORK, ON M3K 0A1	32 CANADIAN FORCES HEALTH SERVICES CENTRE TORONTO DENISON ARMOURY 1 YUKON LANE NORTH YORK, ON M3K 0A1
2 FIELD AMBULANCE CLINIC PHARMACY CANADIAN FORCES BASE PETAWAWA BUILDING N-109 PETAWAWA, ON K8H 2X3	2 FIELD AMBULANCE CLINIC PHARMACY CANADIAN FORCES BASE PETAWAWA BUILDING N-109 PETAWAWA, ON K8H 2X3
2 FIELD AMBULANCE BRIGADE PHARMACY MED COY, BUILDING BB-130 CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3	2 FIELD AMBULANCE BRIGADE PHARMACY MED COY, BUILDING BB-130 CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3
1 CANADIAN FIELD HOSPITAL PHARMACY CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3	1 CANADIAN FIELD HOSPITAL PHARMACY 147 FLANDERS ROW CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3
CENTRAL MEDICAL EQUIPMENT DEPOT CANADIAN FORCES BASE PETAWAWA BUILDING BB-104 CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3	CENTRAL MEDICAL EQUIPMENT DEPOT CANADIAN FORCES BASE PETAWAWA BUILDING BB-104 CANADIAN FORCES BASE PETAWAWA PETAWAWA, ON K8H 2X3

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

CF H SVCS C (OTTAWA) DET GEILENKIRCHEN PO BOX 5053, STN FORCES BELLEVILLE, ON K8N 5W6	CANADIAN FORCES BASE PETAWAWA 105 MONTGOMERY RD CENTRAL MEDICAL EQUIPMENT DEPOT PETAWAWA, ON K8H 2X3
CSOR UMS, CFB PETAWAWA, 46 CENTURION RD, BLDG Z-127, PETAWAWA ONT K8H 2X3	CSOR UMS, CFB PETAWAWA, 46 CENTURION RD, BLDG Z-127, PETAWAWA ONT K8H 2X3
31 CF H SVCS C Det MEAFORD 4TH CDN DIVISION TRG CENTRE RR#1 GREY RD 112 MEAFORD ON N4L 0A1	31 CF H SVCS C Det MEAFORD 4TH CDN DIVISION TRG CENTRE RR#1 GREY RD 112 MEAFORD ON N4L 0A1
31 CANADIAN FORCES HEALTH SERVICES CENTRE BORDEN PHARMACY CANADIAN FORCES BASE BORDEN BUILDING O-166 BORDEN, ON L0M 1C0	31 CF HEALTH SERVICES CENTRE BORDEN PHARMACY CANADIAN FORCES BASE BORDEN BUILDING O-166 BORDEN, ON L0M 1C0
CF HEALTH SERVICES TRAINING CENTRE CFB BORDEN PO BOX 1000 STN MAIN BORDEN ON L0M 1C0	CF HEALTH SERVICES TRAINING CENTRE CFB BORDEN, 30 ORTONA RD, BLDG. 0-166, RM 1563 BORDEN ON, L0M 1C0
25 CANADIAN FORCES HEALTH SERVICES CENTRE BAGOTVILLE 3 WING BFC BAGOTVILLE 3E ESCADRE PHARMACIE, BLDG 66 ALOUETTE, PQ G0V 1A0	25 CF HEALTH SERVICES CENTRE BAGOTVILLE 3 WING BFC BAGOTVILLE 3E ESCADRE PHARMACIE, BLDG 66 ALOUETTE, PQ G0V 1A0
5e AMB de C PHARMACIE CANADIAN FORCES BASE VALCARTIER BUILDING 109 COURCELETTE, PQ G0A 1R0	5e AMB de C PHARMACIE CANADIAN FORCES BASE VALCARTIER BUILDING 109 COURCELETTE, PQ G0A 1R0
DEPOT MATERIEL MEDICAL 5 AMB de C BATISSE 10 CP 1000 SUCC FORCES COURCELETTE PQ G0A 4Z0	DEPOT MATERIEL MEDICAL 5 AMB de C BATISSE 10 COURCELETTE PQ G0A 4Z0
41 CANADIAN FORCES HEALTH SERVICES CENTRE SAINT JEAN PHARMACY CANADIAN FORCES BASE SAINT JEAN BUILDING 150 RICHELAIN, PQ J0J 1R0	41 CANADIAN FORCES HEALTH SERVICES CENTRE SAINT JEAN PHARMACY CANADIAN FORCES BASE SAINT JEAN BUILDING 150 RICHELAIN, PQ J0J 1R0
42 CANADIAN FORCES HEALTH SERVICES CENTRE GAGETOWN PHARMACY CANADIAN FORCES BASE GAGETOWN BUILDING A-47 PO BOX 17000 STN FORCES ORMOCTO, NB E2V 4J5	42 CANADIAN FORCES HEALTH SERVICES CENTRE GAGETOWN PHARMACY CANADIAN FORCES BASE GAGETOWN BUILDING A-47 PO BOX 17000 STN FORCES ORMOCTO, NB E2V 4J5
CANADIAN FORCES HEALTH SERVICES CENTRE (ATLANTIC) PHARMACY MCCALLUM FACILITY, BLDG BLDG S-80 P.O. BOX 99000 STN FORCES HALIFAX, NS B3K 5X5	CANADIAN FORCES HEALTH SERVICES CENTRE (ATLANTIC) PHARMACY MCCALLUM FACILITY, BLDG BLDG S-80 P.O. BOX 99000 STN FORCES HALIFAX, NS B3K 5X5
SHEARWATER MEDICAL CLINIC PHARMACY 12 WING CFB SHEARWATER WARRIOR BLOCK, BUILDING 100 SHEARWATER, NS B0J 3A0	SHEARWATER MEDICAL CLINIC PHARMACY 12 WING CFB SHEARWATER WARRIOR BLOCK, BUILDING 100 SHEARWATER, NS B0J 3A0

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

MEDICAL PROVISION POINT HALIFAX C/O FORMATION HEALTH SERVICES UNIT (ATLANTIC) MCCALLUM FACILITY, BUILDING S-80 HALIFAX, NS B3K 5X5	MEDICAL PROVISION POINT HALIFAX C/O CF HEALTH SERVICES CENTRE (ATLANTIC) MCCALLUM FACILITY, BUILDING S-80 HALIFAX, NS B3K 5X5
26 CANADIAN FORCES HEALTH SERVICES CENTRE GREENWOOD 14 WING CFB GREENWOOD BUILDING 13 GREENWOOD, NS B0P 1N0	26 CF HEALTH SERVICES CENTRE GREENWOOD PHARMACY 14 WING CFB GREENWOOD BUILDING 13 GREENWOOD, NS B0P 1N0
STATION MEDICAL SECTION ST JOHN'S CANADIAN FORCES STATION ST. JOHN'S BUILDING 309 PO BOX 2028 ST JOHN'S, NL A1C 6B5	STATION MEDICAL SECTION ST JOHN'S CANADIAN FORCES STATION ST. JOHN'S BUILDING 309 PO BOX 2028 ST JOHN'S, NL A1C 6B5
BASE PHARMACY CFB GANDER PO BOX STN MAIN GANDER NL A1V 1X1	BASE PHARMACY CFB GANDER PO BOX STN MAIN GANDER NL A1V 1X1
27 CANADIAN FORCES HEALTH SERVICES CENTRE GOOSE BAY CANADIAN FORCES BASE GOOSE BAY GOOSE BAY AIRPORT, STATION A GOOSE BAY, NL A0P 1S0	27 CF HEALTH SERVICES CENTRE GOOSE BAY CANADIAN FORCES BASE GOOSE BAY GOOSE BAY AIRPORT, STATION A GOOSE BAY, NL A0P 1S0
1 FD AMB DET YELLOWKNIFE J TOBIE BLDG 5020 48 ST YELLOWKNIFE NWT X1A 1N3	1 FD AMB DET YELLOWKNIFE J TOBIE BLDG 5020 48 ST YELLOWKNIFE NWT X1A 1N3
Correctional Services Canada	
Billing Addresses	Delivery Addresses
PACIFIC REGIONAL PHARMACY 33344 KING ROAD PO BOX 3000 ABBOTSFORD, BRITISH COLUMBIA V2S 4P4	PACIFIC REGIONAL PHARMACY 33344 KING ROAD PO BOX 3000 ABBOTSFORD, BRITISH COLUMBIA V2S 4P4 ATTN: JASON WONG
REGIONAL PHARMACY PRA 3427 FAITHFUL AVE SASKATOON, SASKATCHEWAN S7K 8H6	REGIONAL PHARMACY PRA 3427 FAITHFUL AVE SASKATOON, SASKATCHEWAN S7K 8H6
ONTARIO REGIONAL PHARMACY FRONTENAC INSTITUTION 1455 BATH ROAD PO BOX 190 KINGSTON, ONTARIO K7L 4V9	ONTARIO REGIONAL PHARMACY FRONTENAC INSTITUTION 1455 BATH ROAD PO BOX 190 KINGSTON, ONTARIO K7L 4V9 ATTN: PAMELA LINDSAY
REGIONAL RECEPTION CENTRE 246 MONTÉE GAGNON SAINTE-ANNE-DES-PLAINES, QUEBEC J0N 1H0	REGIONAL RECEPTION CENTRE 246 MONTÉE GAGNON SAINTE-ANNE-DES-PLAINES, QUEBEC J0N 1H0
ARCHAMBAULT INSTITUTION 242 MONTÉE GAGNON SAINTE-ANNE-DES-PLAINES, QUEBEC J0N 1H0	ARCHAMBAULT INSTITUTION 242 MONTÉE GAGNON SAINTE-ANNE-DES-PLAINES, QUEBEC J0N 1H0
COWANSVILLE INSTITUTION 400 FORDYCE AVENUE COWANSVILLE, QUEBEC J2K 3G6	COWANSVILLE INSTITUTION 400 FORDYCE AVENUE COWANSVILLE, QUEBEC J2K 3G6
DRUMMOND INSTITUTION 2025 JEAN-DE-BRÉBEUF BLVD. DRUMMONDVILLE, QUEBEC J2B 7Z6	DRUMMOND INSTITUTION 2025 JEAN-DE-BRÉBEUF BLVD. DRUMMONDVILLE, QUEBEC J2B 7Z6

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

PORT-CARTIER INSTITUTION CHEMIN DE L'AÉROPORT PO BOX 7070 PORT-CARTIER, QUEBEC G5B 2W2	PORT-CARTIER INSTITUTION CHEMIN DE L'AÉROPORT PO BOX 7070 PORT-CARTIER, QUEBEC G5B 2W2
CENTRE FÉDÉRAL DE FORMATION 6099 BOUL. LÉVESQUE EST LAVAL, QUÉBEC, H7C 1P1	CENTRE FÉDÉRAL DE FORMATION 6099 BOUL. LÉVESQUE EST LAVAL, QUÉBEC, H7C 1P1
PHARMACIE RÉGIONALE – QUÉBEC 5492 BOULEVARD LÉVESQUE EST LAVAL, QUÉBEC, H7C 1N7	PHARMACIE RÉGIONALE – QUÉBEC 5492 BOULEVARD LÉVESQUE EST LAVAL, QUÉBEC, H7C 1N7
CSC- REGIONAL PHARMACY - PHARMACIE RÉGIONALE 1045 MAIN STREET, 2ND FLOOR MONCTON, NNEW BRUNSWICK E1C 1G3	CSC - ATLANTIC INSTITUTION 13175 ROUTE 8 P.O. BOX 102 RENOUS, NEW BRUNSWICK E9E 2E1 TELEPHONE: (506) 623-4000 ATT: HEALTHCARE KARLA MCGRAW
CSC- REGIONAL PHARMACY - PHARMACIE RÉGIONALE 1045 MAIN STREET, 2ND FLOOR MONCTON, NNEW BRUNSWICK E1C 1G3	CSC - WESTMORLAND INSTITUTION 4902A MAIN STREET DORCHESTER, NEW BRUNSWICK E4K 2Y9 TELEPHONE: (506) 379-4595
CSC- REGIONAL PHARMACY - PHARMACIE RÉGIONALE 1045 MAIN STREET, 2ND FLOOR MONCTON, NNEW BRUNSWICK E1C 1G3	CSC - DORCHESTER PENITENTIARY 4902 MAIN STREET DORCHESTER, NEW BRUNSWICK E4K 2Y9 TELEPHONE: (506) 379-2471 ATT: HEALTHCARE TRACY VANDE MEERAKKER
CSC- REGIONAL PHARMACY - PHARMACIE RÉGIONALE 1045 MAIN STREET, 2ND FLOOR MONCTON, NNEW BRUNSWICK E1C 1G3	CSC - SPRINGHILL INSTITUTION 330 MCGEE STREET P.O. BOX 2140 SPRINGHILL, NOVA SCOTIA B0M 1X0 TELEPHONE: (902) 597-8651 ATT: HEALTHCARE SUSAN BEATON
Indigenous Services Canada	
Billing Addresses	Delivery Addresses
INDIGENOUS SERVICES CANADA SUITE 730, 9700 JASPER AVENUE EDMONTON, ALBERTA, T5J 4C3 ATT: JANE SERBEN	INDIGENOUS SERVICES CANADA SUITE 730, 9700 JASPER AVENUE EDMONTON, ALBERTA, T5J 4C3 ATT: JANE SERBEN
ISC - FIRST NATIONS INUIT HEALTH 391 YORK AVE, SUITE 300 WINNIPEG, MB R3C 4W1	ISC - FIRST NATIONS INUIT HEALTH 391 YORK AVE, SUITE 300 WINNIPEG, MB R3C 4W1
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	BLOODVEIN NURSING STATION BLOODVEIN MANITOBA R0C 0J0 PH (204) 395-2161 FAX (204) 395-2087
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	BROCHET NURSING STATION BROCHET, MANITOBA R0B 0B0 PH (204) 323-2120 FAX (204) 323-2650

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	CROSS LAKE NURSING STATION BOX #160 CROSS LAKE, MANITOBA R0B 0J0 PH (204) 676-2011 FAX (204) 676-3179
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	GARDEN HILL NURSING STATION ISLAND LAKE, MANITOBA R0B 0T0 PH (204) 456-2343 FAX (204) 456-2866
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	GOD'S LAKE NARROWS NURSING STATION GOD' S LAKE NARROW S, MANITOBA R0B 0M0 PH (204) 335-2557 FAX (204) 335-2043
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	GOD'S RIVER NURSING STATION GOD' S RIVER, MANITOBA R0B 0N0 PH (204) 366-2355 FAX (204) 366-2474
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	LAC BROCHET NURSING STATION LAC BROCHET, MANITOBA R0B 2E0 PH (204) 337-2161 FAX (204) 337-2143
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	LITTLE GRAND RAPIDS NURSING STATION LITTLE GRAND RAPIDS, MANITOBA R0B 0V0 PH (204) 397-2115 FAX (204) 397-2016
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	NELSON HOUSE NURSING STATION NELSON HOUSE, MANITOBA R0B 1A0 PH (204) 484-2031 FAX (204) 484-2284
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	NORWAY HOUSE HOSPITAL BOX #1060 NORWAY HOUSE, MANITOBA R0B 1B0 PH (204) 359-6731 FAX (204) 359-4113
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	OXFORD HOUSE NURSING STATION OXFORD HOUSE, MANITOBA R0B 1C0 PH (204) 538-2347 FAX (204) 538-2445
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	PAUINGASSI NURSING STATION P.O. BOX 32 PAUINGASSI, MANITOBA R0B 2G0 PH (204) 397-2395 FAX (204) 397-2104
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	POPLAR RIVER NURSING STATION NEGGINAN, MANITOBA R0B 1G0 PH (204) 553-2271 FAX (204) 553-2241

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	PUKATAWAGAN NURSING STATION (BAND) PUKATAWAGAN, MANITOBA R0B 1G0 PH (204) 553-2271 FAX (204) 553-2241
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	RED SUCKER LAKE NURSING STATION RED SUCKER LAKE, MANITOBA R0B 1H0 PH (204) 469-5351 FAX (204) 469-5769
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	SHAMATTAWA NURSING STATION SHAMATTAWA, MANITOBA R0B 1K0 PH (204) 565-2370 FAX (204) 565-2519
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	SOUTH INDIAN LAKE NURSING STATION SOUTH INDIAN LAKE, MANITOBA R0B 1N0 PH (204) 374-2013 FAX (204) 374-2039
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	SPLIT LAKE NURSING STATION SPLIT LAKE, MANITOBA R0B 1P0 PH (204) 342-2033 FAX (204) 342-2319
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	ST. THERESA POINT NURSING STATION ST. THERESA POINT, MANITOBA R0B 1J0 PH (204) 462-2473 FAX (204) 462-2642
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	TADOULE LAKE NURSING STATION TADOULE LAKE, MANITOBA R0B 2C0 PH (204) 684-2031 FAX (204) 684-2049
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	WASAGAMACK NURSING STATION WASAGAMACK, MANITOBA R0B 1Z0 PH (204) 457-2189 FAX (204) 457-2348
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	BERENS RIVER NURSING STATION BERENS RIVER, MANITOBA R0B 0A0 PH (204) 382-2265 FAX (204) 382-2005
INDIGENOUS SERVICES CANADA 300-391 YORK AVENUE WINNIPEG, MANITOBA R3C 4W1	YORK LANDING NURSING STATION YORK LANDING, MANITOBA R0B 2B0 PH (204) 341-2325 FAX (204) 341-2179
Ontario	
Billing Address	Delivery Address
SUPPLY CHAIN AND FACILITIES BRANCH MINISTRY OF HEALTH AND LONG-TERM CARE 99 ADDESSO DRIVE CONCORD, ON L4K 3C7 ATT: LORI CHEWINS, 416-327-0831	ONTARIO GOVERNMENT PHARMACEUTICAL AND MEDICAL SUPPLY SERVICE (OGPMSS) SUPPLY CHAIN AND FACILITIES BRANCH MINISTRY OF HEALTH AND LONG-TERM CARE 99 ADDESSO DRIVE CONCORD, ON L4K 3C7 ATT: ANISA KAZI, 416-326-9136

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

PEI	
Billing Address	Delivery Address
PROVINCIAL PHARMACY P.O. BOX 2000 16 FITZROY STREET CHARLOTTETOWN, PEI C1A 7N8 ATT: BLAMACDONALD@IHIS.ORG	PROVINCIAL PHARMACY P.O. BOX 2000 16 FITZROY STREET CHARLOTTETOWN, PEI C1A 7N8 ATT: BETTY MACDONALD, 902-368-4902
Manitoba	
Billing Address	Delivery Address
WINNIPEG REGIONAL HEALTH AUTHORITY 4TH FLOOR, 650 MAIN STREET WINNIPEG, MB R3B 1E2 ATT: ALISON BOCKSTAEI, 204-926-7163 ABOCKSTAEI@WRHA.MB.CA	THE PRESCRIPTION SHOP #4 100-825 SHERBROOK ST. WINNIPEG, MB R3A 1M5 PH (204) 774-7711 FAX (204) 783-6603

[illegible]

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

Annex D – Return Policy

To be inserted at Contract award

Bidder to include their Return Policy only. Bidder's terms and conditions are not to be included.

Annex E

MANDATORY TECHNICAL CRITERIA

A Bid must meet all Mandatory Criteria (M1-M3). Failure on the part of the Bidder to meet any one (1) of the Mandatory Criteria will result in their bid being deemed non-responsive, and their bid will be given no further consideration.

MANDATORY CRITERIA

M1. Bidders must agree to the *Disclosure of Information - Pharmaceutical Prime Vendor Standing Offer Holder* clause.

The Bidder agrees to appoint Canada's Pharmaceutical Prime Vendor, or another prime distributor as may be the case, as an Authorized Agent for the purposes of:

- (i) receiving and fulfilling orders under the Standing Offer, and
- (ii) receiving payment

Yes _____ No _____

M2. Where the Unit of Measure is per tablet or capsule, Bidders must submit one price per single capsule or tablet. Bidder must agree to keep price per Unit of Measure the same regardless of format size. As an example, if the unit price per tablet is \$0.25, it would remain the same for a bottle of 100 tablets (\$25.00) or 200 tablets (\$50.00).

Yes _____ No _____

M3. Bidder must agree to keep unit prices firm for the entire period of the contract. (i.e. firm year and option years).

Yes _____ No _____

Annex F

Financial Offer

Based on the methodology detailed below, bids meeting all the mandatory criteria will be evaluated on the basis of their financial offer.

1. Price Calculation

Bidders with the lowest responsive price per item will be recommended for contract award.

Items 17, 38, 111, 137, 182, 193, 225, 259, 267, 287, 290, and 305 will be evaluated by the lowest aggregate price per grouping for that item. As an example, the bidder with the lowest aggregate price per grouping for item #17 will be awarded all the products listed in that item.

If bidding on an aggregate grouping, the bidder must submit a price for each item within the grouping. Bids not containing a price for each item will be deemed non-responsive for that grouping.

In Annex A -1, Bidders must fill in their firm unit price per Unit of Measure (U of M) in column (B), titled *Firm Price per U of M*. The unit price contained in Column (B) will be multiplied by the total quantity in Column (A), titled *Maximum Total Estimated Quantities*, to give a total extended price in Column (C) (ex: $A \times B = C$).

The price per unit of measure must remain the same regardless of format size. As an example, if the unit price per was \$0.25, it would remain the same for a bottle of 100 s (\$25.00) or 200 s (\$50.00).

An electronic copy of Annex A-1 will be provided upon request. Please send requests to suzanne.bissonnette@pwgsc.gc.ca 5 days prior to bid closing date and time.

ANNEX G to PART 5 - BID SOLICITATION FEDERAL CONTRACTORS PROGRAM FOR EMPLOYMENT EQUITY - CERTIFICATION

I, the Bidder, by submitting the present information to the Contracting Authority, certify that the information provided is true as of the date indicated below. The certifications provided to Canada are subject to verification at all times. I understand that Canada will declare a bid non-responsive, or will declare a contractor in default, if a certification is found to be untrue, whether during the bid evaluation period or during the contract period. Canada will have the right to ask for additional information to verify the Bidder's certifications. Failure to comply with any request or requirement imposed by Canada may render the bid non-responsive or constitute a default under the Contract.

For further information on the Federal Contractors Program for Employment Equity visit Employment and Social Development Canada (ESDC) - Labour
(http://www.esdc.gc.ca/en/jobs/workplace/human_rights/employment_equity/federal_contractor_program.page) website.

Date : _____ (YYYY/MM/DD) (If left blank, the date will be deemed to be the bid solicitation closing date.)

Complete both A and B.

A. Check only one of the following:

- ☐ A1. The Bidder certifies having no work force in Canada.
- ☐ A2. The Bidder certifies being a public sector employer.
- ☐ A3. The Bidder certifies being a federally regulated employer being subject to the Employment Equity Act.
- ☐ A4. The Bidder certifies having a combined work force in Canada of less than 100 permanent full-time and/or permanent part-time employees.

A5. The Bidder has a combined workforce in Canada of 100 or more employees; and

- ☐ A5.1 the Bidder certifies already having a valid and current Agreement to Implement Employment Equity (AIEE) in place with ESDC-Labour.

OR

- ☐ A5.2. the Bidder certifies having submitted the Agreement to Implement Employment Equity (LAB1168) to ESDC-Labour. As this is a condition to contract award, proceed to completing the form Agreement to Implement Employment Equity (LAB1168), duly signing it, and transmit it to ESDC-Labour.

B. Check only one of the following:

- ☐ B1. The Bidder is not a Joint Venture.

OR

- ☐ B2. The Bidder is a Joint Venture and each member of the Joint Venture must provide the Contracting Authority with a completed annex Federal Contractors Program for Employment Equity - Certification. (Refer to the Joint Venture section of the Standard Instructions)

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

ANNEX H to PART 3 OF THE BID SOLICITATION

1. Electronic Payments Instruments *(As indicated in Part 3, clause 3.1.2, the Bidder must identify which electronic payment instruments they are willing to accept for payment of invoices.)*

The Bidder accepts any of the following Electronic Payment Instrument(s):

- () VISA Acquisition Card;
- () MasterCard Acquisition Card;
- () Direct Deposit (Domestic and International);
- () Electronic Data Interchange (EDI);
- () Wire Transfer (International Only);
- () Large Value Transfer System (LVTS) (Over \$25M)

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

FORM 1 - BID SUBMISSION		
Bidder's full legal name		
Bidder's Address		
Bidder's Procurement Business Number (PBN)		
Province in Canada the Bidder wishes to be the legal jurisdiction applicable to any resulting Contract (if other than as specified in solicitation)		
Contractor Representative – General enquiries	Name	
	Title	
	Telephone #	
	Facsimile #	
	E-mail	
Contractor Representative – Delivery follow-up	Name	
	Title	
	Telephone #	
	Facsimile #	
	E-mail	
Returns	Address to return product	
	Contact Name	
	Telephone #	
	Facsimile #	
	E-mail	
Point of Manufacturing/Shipping	Manufacturing	
	Shipping	

Solicitation No. - N de l'invitation
E60PH-19DRUG/A

Amd. No. - N de la modif.

Buyer ID - Id de l'acheteur
ph895

Client Ref. No. - N de rf. du client

File No. - N du dossier

E60PH-19DRUG

phE60PH-19DRUG

FORM 1 - BID SUBMISSION

Bidders who are incorporated, including those bidding as a joint venture, must provide a complete list of names of all individuals who are currently on the board of directors of the Bidder. Bidders bidding as sole proprietorship, including those bidding as a joint venture, must provide the name of the owner.

On behalf of the Bidder, by signing below, I further confirm that I have read the entire bid solicitation including the documents incorporated by reference into the bid solicitation and:

1. The Bidder considers itself and its Products able to meet all the mandatory requirements described in the bid solicitation;
2. This Bid is valid for the period requested in the bid solicitation;
3. All the information provided in the bid is complete, true and accurate; and
4. If the Bidder is issued a Contract, it will accept all the terms and conditions set out in the resulting contract included in the bid solicitation.

Contractor's Bid Dated

**Signature of Authorized
Representative of Bidder**

ANNEX A-1
STATEMENT OF REQUIREMENT, PRICING AND DELIVERABLES

An electronic copy of the spreadsheet can be requested from the Contracting Authority by sending an e-mail to: suzanne.bissonnette@pwgsc.gc.ca

Item #	Description	CSC Qty	DND Qty	ISC / MB Qty	ISC / ON Qty	ISC / AS Qty	ON Qty***	MB Qty	PE Qty	Total Estimated Quantities	Overage (%)	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (\$)B	Total Extended Price (C)	Canada's Preferred pack size **	DIN	MUST BE COMPLETED BY BIDDER	
																			ALL	format sizes available from Supplier
1	ACETAMINOPHEN DROPS 80 MG/5ML ORAL 240ML				13,000	3,320				16,328	3,266	14,995	19,594	BOTTLE		\$ -	-	240ML		
2	ACETAMINOPHEN LIQUID 160 MG/5ML ORAL 1000ML			11,574	4,000	500				16,074	3,215	14,467	19,289	BOTTLE		\$ -	-	1000ML		
3	ACETAMINOPHEN TABLET 325 MG ORAL 24-30 TABS		279,576		18,816					298,392	59,678	2,68,553	358,070	TABLET		\$ -	-	24-30		
4	ACETAMINOPHEN TABLET 325 MG ORAL	14,000	150,000	1,130,000	106,300		43,000,000			44,400,300	8,880,060	39,960,270	53,280,360	TABLET		\$ -	-	100, 1000		
5	ACETAMINOPHEN TABLET 500 MG ORAL	1,440,000	1,000,000			1,000	37,000,000			39,450,000	7,890,000	35,505,000	47,340,000	TABLET		\$ -	-	100, 500, 1000		
6	ACITRETIN CAPSULE 10 MG ORAL	1,050								1,050	210	945	1,260	CAPSULE		\$ -	-	30		
7	ACITRETIN CAPSULE 25 MG ORAL	1,410								1,410	282	1,269	1,692	CAPSULE		\$ -	-	30		
8	ACYCLOVIR OINT. (G) 5% TOPICAL 30G							50		50	10	45	60	TUBE		\$ -	-	90G		
9	ACYCLOVIR TABLET 200 MG ORAL	890	9,300	2,200						11,890	2,378	10,701	14,268	TABLET		\$ -	-	100		
10	ACYCLOVIR TABLET 400 MG ORAL	2,000	6,200					400		8,600	1,720	7,740	10,320	TABLET		\$ -	-	100		
11	ACYCLOVIR TABLET 800 MG ORAL	200	1,000							1,200	240	1,080	1,440	TABLET		\$ -	-	100		
12	AMIODARONE HCL VIAL 50 MG/ML INTRAVEN		560	220	260	40				1,080	216	972	1,296	VIAL		\$ -	-	1, 10		
13	AMITRIPTYLINE HCL TABLET 10 MG ORAL	53,000	68,200	2,200						123,400	24,680	111,060	148,080	TABLET		\$ -	-	300, 1000		
14	AMITRIPTYLINE HCL TABLET 25 MG ORAL	60,400	33,200							93,600	18,720	84,240	112,320	TABLET		\$ -	-	900, 1000		
15	AMITRIPTYLINE HCL TABLET 50 MG ORAL	110,000	14,500				46,000			210,500	42,100	189,450	252,600	TABLET		\$ -	-	300, 1000		
16	AMITRIPTYLINE HCL TABLET 75 MG ORAL	25,400	3,800							29,200	5,840	26,280	35,040	TABLET		\$ -	-	300, 1000		
17	a) AMLODIPINE BESYLATE TABLET 10 MG ORAL	57,200	60,500							117,700	23,540	105,930	141,240	TABLET		\$ -	-	100		
	b) AMLODIPINE BESYLATE TABLET 2.5 MG ORAL	9,300							15,000	24,300	4,860	21,970	29,160	TABLET		\$ -	-	100		
	c) AMLODIPINE BESYLATE TABLET 5 MG ORAL	91,700	80,000	2,200			60,000		5,000	238,900	47,780	215,010	286,680	TABLET		\$ -	-	100, 500		
18	AMOXICILIN CAPSULE 250 MG ORAL	5,800		10,000	62,300		17,000		200	95,500	19,100	85,950	114,600	CAPSULE		\$ -	-	100		
19	AMOXICILIN CAPSULE 500 MG ORAL	21,500	101,800	148,200	60,100		48,000		200	379,800	75,560	341,820	455,760	CAPSULE		\$ -	-	100, 500		
20	AMOXICILIN SUSP RECON 250 MG/5ML ORAL 1500ML	390		11,000	2,250				3	13,652	2,730	12,287	16,382	BOTTLE		\$ -	-	1500ML		
21	AMOXICILIN/POTASSIUM CLAVY TABLET 500-125 MG ORAL	2,000	14,500						300	16,800	3,360	15,120	20,160	TABLET		\$ -	-	100		
22	AMOXICILIN/POTASSIUM CLAVY TABLET 875-125 MG ORAL	4,170	11,700	12,000	11,100				100	39,070	7,814	35,163	46,884	TABLET		\$ -	-	100		
23	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 10 MG ORAL	500	10,200							10,700	2,140	9,630	12,840	CAPSULE		\$ -	-	100		
24	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 15 MG ORAL	100	3,900							4,000	800	3,600	4,800	CAPSULE		\$ -	-	100		
25	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 20 MG ORAL	1,800	10,500							12,300	2,460	11,070	14,760	CAPSULE		\$ -	-	100		
26	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 25 MG ORAL	300	2,800							2,100	420	1,890	2,520	CAPSULE		\$ -	-	100		
27	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 30 MG ORAL	1,600	7,600							9,200	1,840	8,280	11,040	CAPSULE		\$ -	-	100		
28	AMPHET ASP/ AMPHET/D-AMPHET CAP ER 24H 5 MG ORAL	300	1,600							1,900	380	1,710	2,280	CAPSULE		\$ -	-	100		
29	ARIPIPRAZOLE TABLET 10 MG ORAL	20,910	3,000							23,910	4,782	21,519	28,692	TABLET		\$ -	-	30, 100		

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
30	ARIPRAZOLE TABLET 15 MG ORAL	8,750	720							9,450	1,890	11,340	TABLET		\$ -	30, 100			
31	ARIPRAZOLE TABLET 2 MG ORAL	11,280	43,020							54,300	10,860	65,160	TABLET		\$ -	30, 100			
32	ARIPRAZOLE TABLET 20 MG ORAL	4,950	150							5,100	1,020	6,120	TABLET		\$ -	30, 100			
33	ARIPRAZOLE TABLET 30 MG ORAL	2,280								2,280	456	2,736	TABLET		\$ -	30, 100			
34	ARIPRAZOLE TABLET 5 MG ORAL	15,120	191,110							34,230	6,846	30,807	TABLET		\$ -	30, 100			
35	ATAZANAVIR SULFATE CAPSULE 150 MG ORAL	1,860								1,260	252	1,134	CAPSULE		\$ -	60			
36	ATAZANAVIR SULFATE CAPSULE 200 MG ORAL	1,880								1,080	216	972	CAPSULE		\$ -	60			
37	ATAZANAVIR SULFATE CAPSULE 300 MG ORAL	1,470								1,620	324	1,458	CAPSULE		\$ -	30			
38	a) ATOMOXETINE HCL CAPSULE 10 MG ORAL	4,250	1,530							5,760	1,152	5,184	CAPSULE		\$ -	30			
	b) ATOMOXETINE HCL CAPSULE 100 MG ORAL	720	840							1,560	312	1,872	CAPSULE		\$ -	30			
	c) ATOMOXETINE HCL CAPSULE 18 MG ORAL	644	1,890							2,534	507	2,281	CAPSULE		\$ -	30			
	d) ATOMOXETINE HCL CAPSULE 25 MG ORAL	6,240	4,360							10,500	2,100	9,450	CAPSULE		\$ -	30			
	e) ATOMOXETINE HCL CAPSULE 40 MG ORAL	12,460	7,800							20,460	4,092	18,414	CAPSULE		\$ -	30			
	f) ATOMOXETINE HCL CAPSULE 60 MG ORAL	2,220	3,360							5,580	1,116	5,022	CAPSULE		\$ -	30			
	g) ATOMOXETINE HCL CAPSULE 80 MG ORAL	2,100	1,830							3,930	786	3,537	CAPSULE		\$ -	30, 80			
39	ATORVASTATIN CALCIUM TABLET 10 MG ORAL	62,300	120,000				30,000			216,100	43,220	194,480	TABLET		\$ -	100, 500			
40	ATORVASTATIN CALCIUM TABLET 20 MG ORAL	101,600	170,000						6,000	277,600	55,520	249,840	TABLET		\$ -	100			
41	ATORVASTATIN CALCIUM TABLET 40 MG ORAL	96,300	108,700							205,000	41,000	184,500	TABLET		\$ -	100			
42	ATORVASTATIN CALCIUM TABLET 80 MG ORAL	33,300	25,200							58,500	11,700	52,650	TAB PC		\$ -	90, 100			
43	ATOVAQUONE/ PROGUANIL HCL TABLET 250-100MG ORAL		211,728							211,728	42,346	190,555	TABLET		\$ -	12, 100			
44	BACITRACIN/POLYMX B SULF OINT. (G) 500-10K/G TOP 30G	881	3,350			100				3,631	726	3,268	TU RE		\$ -	30G			
45	BACITRACIN/POLYMX B SULF OINT. (G) 500-10K/G TOP 15G		3,350	20,000	3,481					26,831	5,366	24,148	TUBE		\$ -	15G			
46	BACLOFEN TABLET 10 MG ORAL	30,100	40,100							70,200	14,040	63,180	TABLET		\$ -	100			
47	BECLOMETHASONE DIPROPIONATE SPRAY 50 MCG NASAL 200DS									746	149	672	NASAL SPRAY		\$ -	200DS			
48	BETAMETHASONE VALERATE CREAM (G) 0.05% TOPICAL 450G	50								50	10	45	JAR		\$ -	40G			
49	BETAMETHASONE VALERATE CREAM (G) 0.10% TOPICAL 450G	802								892	178	802	JAR		\$ -	40G			
50	BETAMETHASONE VALERATE CREAM (G) 0.10% TOPICAL 15G				1,343					1,543	309	1,389	TUBE		\$ -	15G			
51	BISACODYL TABLET DR 5 MG ORAL	3,000	18,000				1,500,000			1,521,000	304,200	1,368,900	TABLET		\$ -	100			
52	BUPROPION HCL TAB ER 24H 150 MG ORAL	22,660	183,690				40,500			246,240	49,248	221,616	TABLET		\$ -	90			
53	BUPROPION HCL TAB ER 24H 300 MG ORAL	26,800	128,700				40,500			195,120	39,024	175,608	TABLET		\$ -	90			
54	BUPROPION HCL TABLET ER 100 MG ORAL	13,260	14,850							28,110	5,622	25,299	TABLET		\$ -	60, 90			
55	BUPROPION HCL TABLET ER 150 MG ORAL		26,730				10,800			37,530	7,506	33,777	TABLET		\$ -	60, 90			
56	BUSPIRONE HCL TABLET 10 MG ORAL	181,900	24,500				140,000			346,000	69,200	311,400	TABLET		\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Minimum Work Guarantee (7%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
57	CEFTRIAZONE SODIUM VIAL 1 G INJECTION	1,200	470	11,570	3,370	1,000				17,610	3,522	15,849	VIAL		\$ -	10			
58	CELECOXIB CAPSULE 100 MG ORAL	24,900	68,400							93,300	18,640	83,970	CAPSULE		\$ -	100,500			
59	CELECOXIB CAPSULE 200 MG ORAL	37,000	54,800							91,800	18,360	82,520	CAPSULE		\$ -	100,500			
60	CEPHALEXIN MONOHYDRATE SUSP RECON 250 MG/5ML ORAL 100ML			7,370						7,370	1,474	6,633	BOTTLE		\$ -	1000ML			
61	CEPHALEXIN MONOHYDRATE SUSP RECON 250 MG/5ML ORAL 1500ML				16,083					16,083	3,217	14,475	BOTTLE		\$ -	1500ML			
62	CEPHALEXIN MONOHYDRATE TABLET 250 MG ORAL	5,700	4,700	12,000	18,400					40,800	8,160	36,720	TABLET		\$ -	100			
63	CEPHALEXIN MONOHYDRATE TABLET 500 MG ORAL	21,000	81,000	100,000	72,000					274,000	54,980	247,410	TABLET		\$ -	100,500			
64	CETIRIZINE HCL TABLET 10 MG ORAL	232,990	365,000	2,100	8,370		90,000		7,000	705,060	141,012	634,554	TABLET		\$ -	18, 100			
65	CETIRIZINE HCL TABLET 20 MG ORAL	1,500	31,200							32,700	6,540	29,430	TABLET		\$ -	100			
66	CHLORHEXIDINE GLUCONATE MOUTHWASH 0.12% MUCOUS MEM	283	2,600							2,883	577	2,595	BOTTLE		\$ -	Between 425-500ML			
67	CLAZAPRIL TABLET 5 MG ORAL		82,500							82,500	16,500	74,250	TABLET		\$ -	100			
68	CLAZAPRIL/HYDROCHLOROTHIAZIDE TAB 5MG-12.5MG ORAL		41,600							41,600	8,320	37,440	TABLET		\$ -	100			
69	CIPROFLOXACIN HCL TABLET 250 MG ORAL	6,200	3,600	4,400	6,300					20,700	4,140	18,630	TABLET		\$ -	100			
70	CIPROFLOXACIN HCL TABLET 500 MG ORAL	6,100	38,000							44,100	8,820	39,690	TABLET		\$ -	100			
71	CIPROFLOXACIN LACTATE/DS W PIGGYBACK 2 MG/ML INTRAV	24	3,000							3,024	605	2,722	SOLUTION		\$ -	1, 24			
72	CITALOPRAM HYDROBROMIDE TABLET 10 MG ORAL	50,200	47,800							98,000	19,600	88,200	TABLET		\$ -	100			
73	CITALOPRAM HYDROBROMIDE TABLET 20 MG ORAL	78,500	300,000				50,000		15,000	443,500	88,700	399,150	TABLET		\$ -	100,500			
74	CITALOPRAM HYDROBROMIDE TABLET 40 MG ORAL	21,000	75,000							100,000	20,000	90,000	TABLET		\$ -	100			
75	CLARITHROMYCIN TAB ER 24H 500 MG ORAL		5,500							5,500	1,100	4,950	TABLET		\$ -	100			
76	CLARITHROMYCIN TABLET 250 MG ORAL	5,700	2,800							8,500	1,700	7,650	TABLET		\$ -	100			
77	CLARITHROMYCIN TABLET 500 MG ORAL	1,400	20,600							22,000	4,400	19,800	TABLET		\$ -	100			
78	CLINDAMYCIN HCL CAPSULE 150 MG ORAL	16,600	12,500	50,000	41,700					120,800	24,160	108,720	CAPSULE		\$ -	100			
79	CLINDAMYCIN HCL CAPSULE 300 MG ORAL	9,810	22,500				30,000			62,710	12,542	56,439	CAPSULE		\$ -	100			
80	CLINDAMYCIN PHOS/BENZDYL PERK GEL ENG 1% 5% TOP	640	321							961	192	865	PUMP		\$ -	Between 60-60G			
81	CLINDAMYCIN PHOSPHATE VIAL 150 MG/ML INJECTION	56		7,200	3,000					10,250	2,050	9,225	VIAL		\$ -				
82	CLONIDINE HCL TABLET 0.025 MG ORAL	16,100								16,100	3,220	14,980	TABLET		\$ -	100			
83	CLONIDINE HCL TABLET 0.1 MG ORAL	105,800	9,900	2,100						117,800	23,560	106,020	TABLET		\$ -	100			
84	CLONIDINE HCL TABLET 0.2 MG ORAL	12,900								12,900	2,580	11,610	TABLET		\$ -	100			
85	CLOPIDOGREL BISULFATE TABLET 75 MG ORAL	26,800	18,100	300						45,200	9,040	40,680	TABLET		\$ -	30, 100			
86	CLOTIMAZOLE CREAM (G) 1% TOPICAL 500G	94								94	19	85	JAR		\$ -	500G			
87	CLOTIMAZOLE CREAM (G) 1% TOPICAL 30G		4,476		1,306				150	5,932	1,186	5,339	TUBE		\$ -	30G			
88	CLOZAPINE TABLET 100 MG ORAL	50,400								50,400	10,080	45,360	TABLET		\$ -	100			
89	CLOZAPINE TABLET 25 MG ORAL	29,300								29,300	5,860	26,370	TABLET		\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	ALL for mat sizes available from Supplier	Supplier's product number(s)
90	CYCLOBENZAPRINE HCL TABLET 10 MG ORAL	30,300	132,000				75,000			237,300	47,660	213,570	284,760	TABLET	\$ -	\$ -	100			
91	CYCLOSPORINE, MODIFIED CAPSULE 100 MG ORAL	1,800	1,350						3,000	6,300	1,266	5,697	7,596	CAPSULE	\$ -	\$ -	30			
92	CYCLOSPORINE, MODIFIED CAPSULE 75 MG ORAL	2,400							6,000	8,400	1,686	7,587	10,116	CAPSULE	\$ -	\$ -	30			
93	CYCLOSPORINE, MODIFIED CAPSULE 50 MG ORAL	180	1,100						2,000	3,280	656	2,952	3,936	CAPSULE	\$ -	\$ -	30			
94	DESVENAFAXINE SUCINATE TAB ER 24H 100 MG ORAL	120	66,500							66,620	13,324	59,958	79,944	TABLET	\$ -	\$ -	30, 100			
95	DESVENAFAXINE SUCINATE TAB ER 24H 50 MG ORAL	2,500	55,600							58,180	11,636	52,862	69,816	TABLET	\$ -	\$ -	30, 100			
96	DEXTROAMPHETAMINE SULFATE CAPSULE ER 10 MG ORAL	3,700	14,900							18,600	3,720	16,740	22,320	CAPSULE	\$ -	\$ -	100			
97	DEXTROAMPHETAMINE SULFATE CAPSULE ER 15 MG ORAL	2,600	6,400							9,000	1,800	8,100	10,800	CAPSULE	\$ -	\$ -	100			
98	DEXTROAMPHETAMINE SULFATE TABLET 5 MG ORAL	13,600	19,200							32,800	6,560	29,520	39,360	TABLET	\$ -	\$ -	100			
99	DEXTROMETHORPHAN HBR SYRUP 15 MG/5 ML ORAL 100ML	52								52	10	46	62	BOTTLE	\$ -	\$ -	100ML			
100	DEXTROMETHORPHAN HBR SYRUP 15 MG/5 ML ORAL 250ML						14,000			14,000	2,800	12,600	16,800	BOTTLE	\$ -	\$ -	250ML			
101	DIAZEPAM AMPUL 5 MG/ML INJECTION	190			200					420	84	378	504	AMPUL	\$ -	\$ -	10			
102	DICLOFENAC SOD/MI SOPROSTOL TAB DR 50 MG-200 ORAL	71,300								71,300	14,660	65,970	87,960	TABLET	\$ -	\$ -	100			
103	DICLOFENAC SODIUM TABLET DR 25 MG ORAL	4,000								4,000	800	3,600	4,800	TABLET	\$ -	\$ -	100			
104	DICLOFENAC SODIUM TABLET DR 50 MG ORAL	42,300	26,700							69,000	13,800	62,100	82,800	TABLET	\$ -	\$ -	100			
105	DICLOFENAC SODIUM TABLET ER 75 MG ORAL	4,100	45,100							49,200	9,840	44,280	59,040	TABLET	\$ -	\$ -	100			
106	DIMENHYDRINATE TABLET 50 MG ORAL	25,724	150,200	420,000	23,300				200	620,134	124,027	558,121	744,161	TABLET	\$ -	\$ -	100			
107	DIPHENHYDRAMINE HCL TABLET 25 MG ORAL	7,500	60,900	33,500	17,100		860,000		400	979,400	195,880	881,460	1,175,280	TABLET	\$ -	\$ -	100, 250			
108	DIPHENHYDRAMINE HCL TABLET 50 MG ORAL	7,500	35,000				300,000			342,500	68,500	308,250	411,000	TABLET	\$ -	\$ -	100			
109	DIPHENHYDRAMINE HCL VIAL 50 MG/ML INJECTION 25xML	1,185								1,185	237	1,067	1,422	VIAL	\$ -	\$ -	25			
110	DIPHENHYDRAMINE HCL VIAL 50 MG/ML INJECTION 10x1ML			880	260					1,130	226	1,017	1,356	VIAL	\$ -	\$ -	10			
111	a) DIVALPROX SODIUM TABLET DR 250 MG ORAL	12,300	11,700				75,600		500	99,500	19,900	89,550	119,400	TABLET	\$ -	\$ -	100			
	b) DIVALPROX SODIUM TABLET DR 500 MG ORAL	33,200	7,000						200	40,400	8,080	36,360	48,480	TABLET	\$ -	\$ -	100			
112	DOCUSATE SODIUM CAPSULE 100 MG ORAL	201,300								201,300	40,260	181,170	241,560	CAPSULE	\$ -	\$ -	100			
113	DOXEPIN HCL CAPSULE 10 MG ORAL	7,800								7,800	1,560	7,020	9,360	CAPSULE	\$ -	\$ -	100			
114	DOXEPIN HCL CAPSULE 100 MG ORAL	12,600								12,600	2,520	11,340	15,120	CAPSULE	\$ -	\$ -	100			
115	DOXEPIN HCL CAPSULE 25 MG ORAL	7,500								7,500	1,500	6,750	9,000	CAPSULE	\$ -	\$ -	100			
116	DOXEPIN HCL CAPSULE 50 MG ORAL	10,100					55,600			65,100	13,020	58,590	78,120	CAPSULE	\$ -	\$ -	100			
117	DOXEPIN HCL CAPSULE 75 MG ORAL	10,200								10,200	2,040	9,180	12,240	CAPSULE	\$ -	\$ -	100			
118	DOXYLAMINE/PYRIDOXINE HCL TABLET DR 10MG-10MG ORAL	1,200	28,200	3,000	7,800					40,200	8,040	36,180	48,240	TABLET	\$ -	\$ -	100, 300			
119	DULOXETINE HCL CAPSULE DR 30 MG ORAL	46,600	90,200				35,600		1,500	173,300	34,660	155,970	207,860	CAPSULE	\$ -	\$ -	100			
120	DULOXETINE HCL CAPSULE DR 60 MG ORAL	52,500	85,600				30,000		500	168,600	33,720	151,740	202,320	CAPSULE	\$ -	\$ -	28, 100			
121	EFAVIRENZ/EMTRICITAB/TENOFOVIR TAB 600-200MG ORAL	1,800							780	2,610	522	2,349	3,132	TABLET	\$ -	\$ -	30			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (7%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	ALL for mat sizes available from Supplier	Supplier's product number(s)
122	EMTRICITABINE/ TENOFOVIR TABLET 200-300MG ORAL	7,620	171,130						2,500	27,250	5,450	24,525	32,700	TABLET	\$ -	\$ -	30			
123	ERYTHROMYCIN BASE OINT. (G) 5MG/G OPHTHALMIC 3.5G	146				100				754	151	679	905	TUBE	\$ -	\$ -	1			
124	ERYTHROMYCIN BASE OINT. (G) 5MG/G OPHTHALMIC 1G									3,900	780	3,510	4,680	TUBE	\$ -	\$ -	50			
125	ESCITALOPRAM OXALATE TABLET 10 MG ORAL		169,050				100,000			349,050	69,810	314,145	418,860	TABLET	\$ -	\$ -	30, 100			
126	ESCITALOPRAM OXALATE TABLET 20 MG ORAL	80,900	113,100							194,000	38,800	174,600	232,800	TABLET	\$ -	\$ -	30, 100			
127	ESOMEPRAZOLE MAGNESIUM TABLET DR 20 MG ORAL	34,800	9,750							44,550	8,910	40,095	53,460	TABLET	\$ -	\$ -	10, 30, 100			
128	ESOMEPRAZOLE MAGNESIUM TABLET DR 40 MG ORAL	1,200	45,000							46,200	9,240	41,580	55,440	TABLET	\$ -	\$ -	10, 30, 100			
129	EZETIMIBE TABLET 10 MG ORAL	19,200	28,500							47,700	9,540	42,930	57,240	TABLET	\$ -	\$ -	100			
130	FAMCICLOVIR TABLET 125 MG ORAL	1,260	450							1,710	342	1,539	2,052	TABLET	\$ -	\$ -	30			
131	FAMCICLOVIR TABLET 250 MG ORAL	240	11,700							11,940	2,388	10,746	14,328	TABLET	\$ -	\$ -	30			
132	FAMCICLOVIR TABLET 500 MG ORAL	900	12,330							13,260	2,652	11,934	15,912	TABLET	\$ -	\$ -	30			
133	FENOFIBRATE MICRONIZED CAPSULE 300 MG ORAL	17,400	21,000							40,400	8,080	36,360	48,480	CAPSULE	\$ -	\$ -	100			
134	FLUCONAZOLE CAPSULE 150 MG ORAL	131		220	485					836	167	752	1,003	CAPSULE	\$ -	\$ -	1			
135	FLUCONAZOLE TABLET 100 MG ORAL	1,050	2,450							3,500	700	3,150	4,200	TABLET	\$ -	\$ -	50			
136	FLUCONAZOLE TABLET 50 MG ORAL	500	5,850							6,350	1,270	5,715	7,620	TABLET	\$ -	\$ -	50, 100			
137	a) FLUORETINE HCL CAPSULE 10 MG ORAL b) FLUORETINE HCL CAPSULE 20 MG ORAL		42,200							42,200	8,440	37,980	50,640	CAPSULE	\$ -	\$ -	100			
138	FLUTICASON PROPRIONATE SPRAY SUSP 50 MCG NASAL 120DS	102,000	74,800						50	176,800	35,360	159,120	212,160	CAPSULE	\$ -	\$ -	100, 500			
139	GABAPENTIN CAPSULE 100 MG ORAL	107					510			757	151	681	909	NASAL SPRAY	\$ -	\$ -	120DS			
140	GABAPENTIN CAPSULE 300 MG ORAL	32,000	45,000				36,000			112,000	22,400	100,800	134,400	CAPSULE	\$ -	\$ -	100, 500			
141	GABAPENTIN CAPSULE 400 MG ORAL	11,500	96,500				140,000			248,000	49,600	223,200	297,600	CAPSULE	\$ -	\$ -	100, 500			
142	GABAPENTIN TABLET 600 MG ORAL	300,900	25,000				86,000			101,900	20,380	91,710	122,380	CAPSULE	\$ -	\$ -	100, 500			
143	GABAPENTIN TABLET 800 MG ORAL	77,900	1,800							345,900	69,180	311,310	415,080	TABLET	\$ -	\$ -	100, 500			
144	GLICLAZIDE TAB ER 24H 30 MG ORAL	87,400	36,780							79,700	15,940	71,730	95,640	TABLET	\$ -	\$ -	100, 500			
145	GLICLAZIDE TAB ER 24H 60 MG ORAL	13,900	35,400							124,180	24,836	111,762	149,016	TABLET	\$ -	\$ -	60, 100			
146	GLICLAZIDE TABLET 80 MG ORAL	21,000	30,700	2,100						49,300	9,860	44,370	59,160	TABLET	\$ -	\$ -	60, 100			
147	GRAMICIDIN D/POLYMYXIN B SULF CHW(G) 0.25-10K/G TOP 15G	312			3,485					53,800	10,760	48,420	64,560	TABLET	\$ -	\$ -	60, 100			
148	GRAMICIDIN D/POLYMYXIN B SULF DRP 0.025-10K OPHTH 15ML	416	1,893							3,797	759	3,417	4,556	TUBE	\$ -	\$ -	1			
149	HYDROCORT ACETAT/ZN SULF OINT (G) 0.5%-0.5% RECTAL 30G	815		100	996					3,305	661	2,975	3,946	BOTTLE	\$ -	\$ -	1			
150	HYDROCORT ACETAT/ZN SULF SUPP- 10MG-10MG RECTAL	4,936		1,560	862					1,015	203	913	1,217	TUBE	\$ -	\$ -	12			
151	IBUPROFEN ORAL SUSP 100 MG/5ML ORAL 100ML				5,115					7,346	1,470	6,613	8,817	SUPPOS	\$ -	\$ -	12			
152	IBUPROFEN TABLET 200 MG ORAL	66,900	250,800	88,000	245,800					5,137	1,027	4,623	6,164	BOTTLE	\$ -	\$ -	1			
153	IBUPROFEN TABLET 300 MG ORAL	22,100								651,500	130,300	586,350	781,800	TABLET	\$ -	\$ -	100			
										22,100	4,420	19,890	26,520	TABLET	\$ -	\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (7%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
154	IBUPROFEN TABLET 400 MG ORAL	348,832	825,000				180,000			1,353,832	270,766	1,218,449	1,624,598	TABLET	\$ -	\$ -	24, 100			
155	IBUPROFEN TABLET 600 MG ORAL	425,000	63,700				280,000			760,700	153,740	691,830	922,440	TABLET	\$ -	\$ -	100, 500			
156	INDOMETHACIN CAPSULE 25 MG ORAL	26,000	10,400							36,400	7,280	32,760	43,680	CAPSULE	\$ -	\$ -	100			
157	INDOMETHACIN CAPSULE 50 MG ORAL	110,900	15,800							126,300	25,260	113,670	151,560	CAPSULE	\$ -	\$ -	100, 500			
158	ISOTRETINOIN CAPSULE 10 MG ORAL	4,320	13,590							17,910	3,582	16,119	21,492	CAPSULE	\$ -	\$ -	30			
159	ISOTRETINOIN CAPSULE 40 MG ORAL	3,480	15,540							19,020	3,804	17,118	22,824	CAPSULE	\$ -	\$ -	30			
160	KETOROLAC TROMETHAMINE TABLET 10 MG ORAL	19,000					30,000			49,000	9,800	44,100	58,800	TABLET	\$ -	\$ -	100, 500			
161	KETOROLAC TROMETHAMINE VIAL 30MG/ML(1) INTRAMUSC	1,538		4,030	2,860	100				8,318	1,664	7,486	9,981	VIAL	\$ -	\$ -	1, 10			
162	LACTULOSE SOLUTION 10 G/15 ML ORAL	2,348	1,694	40	60					4,142	828	3,728	4,970	BOTTLE	\$ -	\$ -	1			
163	LAMIVUDINE TABLET 150 MG ORAL	800								800	160	720	960	TABLET	\$ -	\$ -	100			
164	LAMIVUDINE/ZIDOVUDINE TABLET 150-300MG ORAL	660								660	132	594	792	TABLET	\$ -	\$ -	60			
165	LANSOPRAZOLE CAPSULE DR 15 MG ORAL	700								700	140	630	840	CAPSULE	\$ -	\$ -	100			
166	LANSOPRAZOLE CAPSULE DR 30 MG ORAL	7,200	39,500							46,700	9,340	42,030	56,040	CAPSULE	\$ -	\$ -	100			
167	LEVETIRACETAM TABLET 500 MG ORAL	26,160	19,100							45,260	9,052	40,734	54,312	TABLET	\$ -	\$ -	100, 120			
168	LEVETIRACETAM TABLET 750 MG ORAL	2,000								2,040	408	1,856	2,448	TABLET	\$ -	\$ -	120			
169	LEVOROXACIN TABLET 250 MG ORAL	900								900	180	810	1,080	TABLET	\$ -	\$ -	100			
170	LEVOROXACIN TABLET 500 MG ORAL	500								500	100	450	600	TABLET	\$ -	\$ -	100			
171	LEVOROXACIN TABLET 750 MG ORAL	700		1,050	4,300					6,650	1,330	5,985	7,980	TABLET	\$ -	\$ -	100			
172	LEVONORGESTREL-ETH ESTRA TABLET 0.1-0.02 ORAL	21	3,900							3,900	780	3,510	4,680	PACK	\$ -	\$ -	21			
173	LEVONORGESTREL-ETH ESTRA TABLET 0.1-0.02 ORAL 2	28	54	2,200	80					2,334	467	2,101	2,801	PACK	\$ -	\$ -	28			
174	LEVONORGESTREL-ETH ESTRA TABLET 0.15-0.03 ORAL	21	240							240	48	216	288	PACK	\$ -	\$ -	21			
175	LEVONORGESTREL-ETH ESTRA TABLET 0.15-0.03 ORAL	28	35	675						710	142	639	852	PACK	\$ -	\$ -	28			
176	LIDOCAINE HCL/PF AMPUL 10 MG/ML INJECTION			1,100	1,100					2,446	489	2,201	2,935	AMPUL	\$ -	\$ -	20, 50			
177	LOPRAAMIDE HCL TABLET 2 MG ORAL	27,876	79,596	4,400						111,872	22,374	100,685	134,246	TABLET	\$ -	\$ -	12, 24, 100			
178	LORATADINE TABLET 10 MG ORAL	30,100	131,500							161,600	32,320	145,440	193,920	TABLET	\$ -	\$ -	100			
179	MISALAZINE TABLET DR 400 MG ORAL	97,000	18,720							115,720	23,144	104,148	138,864	TABLET	\$ -	\$ -	between 180-500			
180	METFORMIN HCL TABLET 500 MG ORAL	986,800	625,400	4,400	8,300		110,000			1,355,100	271,020	1,219,590	1,626,120	TABLET	\$ -	\$ -	between 100- 500			
181	METFORMIN HCL TABLET 850 MG ORAL	36,000	60,000							96,000	19,200	86,400	115,200	TABLET	\$ -	\$ -	100, 500			
182	a) METHYLPHENIDATE HCL TAB ER 24 18 MG ORAL	1,200	19,800							21,000	4,200	18,900	25,200	TABLET	\$ -	\$ -	100			
	b) METHYLPHENIDATE HCL TAB ER 24 27 MG ORAL	3,000	16,000							19,000	3,800	17,100	23,800	TABLET	\$ -	\$ -	100			
	c) METHYLPHENIDATE HCL TAB ER 24 36 MG ORAL	7,300	38,000							45,300	9,060	40,770	54,360	TABLET	\$ -	\$ -	100			
	d) METHYLPHENIDATE HCL TAB ER 24 54 MG ORAL	1,400	27,000							28,400	5,680	25,560	34,080	TABLET	\$ -	\$ -	100			
	e) METHYLPHENIDATE HCL TABLET 10 MG ORAL	152,000	46,800							198,800	39,760	178,920	238,560	TABLET	\$ -	\$ -	100, 500			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
	f) METHYLPHENIDATE HCL TABLET 20 MG ORAL	65,000	10,200							75,200	15,040	90,240	TABLET	\$ -	\$ -	100			
	g) METHYLPHENIDATE HCL TABLET 5 MG ORAL	1,600	6,700							8,300	1,660	9,960	TABLET	\$ -	\$ -	100			
	h) METHYLPHENIDATE HCL TABLET ER 20 MG ORAL	6,200	20,000							26,200	5,240	31,440	TABLET	\$ -	\$ -	100			
	i) METHYLPHENIDATE HCL TABLET ER 20 MG ORAL	16,200	26,200							42,400	8,480	50,880	CAPSULE	\$ -	\$ -	100			
183	MINOCYCLINE HCL CAPSULE 100 MG ORAL																		
184	MINOCYCLINE HCL CAPSULE 50 MG ORAL	5,700	18,500							24,200	4,840	29,040	CAPSULE	\$ -	\$ -	100			
185	MIRTAZAPINE TABLET 15 MG ORAL	77,940	25,100						13,800	116,240	23,248	139,488	TABLET	\$ -	\$ -	30, 100			
186	MIRTAZAPINE TABLET 30 MG ORAL	222,400	25,000				100,000		800	429,200	85,640	513,840	TABLET	\$ -	\$ -	100			
187	MIRTAZAPINE TABLET 45 MG ORAL	50,000	2,600						600	53,200	10,640	63,840	TABLET	\$ -	\$ -	100			
188	MONOMETASONE FURIOATE SPRAY/PUMP 50 MGCS NASAL 1400DS	478	5,900				1,100			7,478	1,496	8,974	NASAL SPRAY	\$ -	\$ -	1			
189	MONTELUKAST SODIUM TABLET 10 MG ORAL	6,600	34,500							41,100	8,238	49,428	TABLET	\$ -	\$ -	30			
190	MORPHINE SULFATE AMPUL 10 MG/ML INJECTION	270				980				850	170	1,020	AMPUL	\$ -	\$ -	10			
191	MYCOPHENOLATE MOFETIL CAPSULE 250 MG ORAL	200								200	40	180	CAPSULE	\$ -	\$ -	100			
192	MYCOPHENOLATE MOFETIL TABLET 500 MG ORAL	4,100	4,800							8,900	1,780	10,680	TABLET	\$ -	\$ -	50, 100			
193	a) NABILONE CAPSULE 0.25 MG ORAL	1,600	45,000							46,600	9,320	55,920	CAPSULE	\$ -	\$ -	50, 100			
	b) NABILONE CAPSULE 0.5 MG ORAL	1,500	30,000							31,500	6,300	37,800	CAPSULE	\$ -	\$ -	100			
	c) NABILONE CAPSULE 1 MG ORAL	6,000	56,700							62,700	12,540	75,240	CAPSULE	\$ -	\$ -	100			
194	NALOXONE HCL VIAL 0.4 MG/ML INJECTION	1,800		4,400	280	300	70,000	3,200		79,980	15,996	95,976	VIAL	\$ -	\$ -	1, 10			
195	NALTREXONE HCL TABLET 50 MG ORAL	360								350	70	420	TABLET	\$ -	\$ -	50			
196	NAPROXEN TABLET 250 MG ORAL	86,600	40,000	50,000	52,800		90,000			319,400	63,880	383,280	TABLET	\$ -	\$ -	100			
197	NAPROXEN TABLET 375 MG ORAL	19,400	21,900							41,300	8,260	49,560	TABLET	\$ -	\$ -	100			
198	NAPROXEN TABLET 500 MG ORAL	115,900	366,200				100,000			581,700	116,340	698,040	TABLET	\$ -	\$ -	100, 500			
199	NAPROXEN TABLET DR 250 MG ORAL	900	7,000							7,900	1,580	9,480	TABLET	\$ -	\$ -	100			
200	NAPROXEN TABLET DR 375 MG ORAL	2,200	9,800							12,000	2,400	14,400	TABLET	\$ -	\$ -	100			
201	NAPROXEN TABLET DR 500 MG ORAL	16,600	121,000							137,600	27,520	165,120	TABLET	\$ -	\$ -	100			
202	NIFEDIPINE TAB ER 24 30 MG ORAL		10,600							10,600	2,120	9,540	TABLET	\$ -	\$ -	100			
203	NIFEDIPINE TAB ER 24 60 MG ORAL		9,800							9,800	1,960	8,820	TABLET	\$ -	\$ -	100			
204	NITROFURANTOIN MONOHYD/M-CRYST CAPSULE 100 MG ORAL	3,300		11,000	18,400					32,700	6,540	39,240	CAPSULE	\$ -	\$ -	100			
205	NITROGLYCERIN SPRAY 400MGCS/SPR SURLING 2000DS		550	88	83		250			971	194	874	SPRAY	\$ -	\$ -	1			
206	NORGESTIMATE-ETHINYL ESTRADIOL TAB 70AYSX3 LO ORAL	967	21,420							21,987	4,397	19,788	TABLET	\$ -	\$ -	21, 28			
207	NORMAL SALINE AMPUL 0.90% INJECTION 10ML	60		4,400						4,460	892	4,014	AMPUL	\$ -	\$ -	20			
208	NORMAL SALINE IV SOLN 0.90% INTRAVEN 100ML	4		10,560						10,564	2,113	9,508	SOLUTION	\$ -	\$ -	4, 16			
209	NORMAL SALINE VIAL 0.90% INJECTION 50ML	25								25	5	23	VIAL	\$ -	\$ -	25			
210	NYSTATIN ORAL SUSP 100000/ML ORAL 100ML		122			360				472	94	567	SUSPENSION	\$ -	\$ -	1			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
211	OLANAPINE TAB RAPIDS 10 MG ORAL	36,750	300	660	750		66,000			104,460	20,892	94,014	125,552	TABLET	\$ -	\$ -	30			
212	OLANAPINE TAB RAPIDS 15 MG ORAL	11,070					18,000			29,670	5,934	26,703	33,604	TABLET	\$ -	\$ -	30			
213	OLANAPINE TAB RAPIDS 20 MG ORAL	8,100					19,500			27,690	5,538	24,921	33,328	TABLET	\$ -	\$ -	30			
214	OLANAPINE TAB RAPIDS 5 MG ORAL	31,600					60,000			93,600	18,720	84,240	112,320	TABLET	\$ -	\$ -	30			
215	OLANAPINE TABLET 10 MG ORAL	70,500	1,700				27,600		830	101,020	20,204	90,918	121,224	TABLET	\$ -	\$ -	100, 500			
216	OLANAPINE TABLET 15 MG ORAL	16,900								16,900	3,380	15,210	20,280	TABLET	\$ -	\$ -	100			
217	OLANAPINE TABLET 2.5 MG ORAL	18,200	4,500						2,000	24,700	4,940	22,230	29,640	TABLET	\$ -	\$ -	100			
218	OLANAPINE TABLET 20 MG ORAL	400								400	80	360	480	TABLET	\$ -	\$ -	100			
219	OLANAPINE TABLET 5 MG ORAL	44,100	3,200						1,700	49,000	9,800	44,100	58,800	TABLET	\$ -	\$ -	100			
220	OLANAPINE TABLET 7.5 MG ORAL	4,900							500	5,400	1,080	4,860	6,480	TABLET	\$ -	\$ -	100			
221	ONMEPRAZOLE CAPSULE DR 20 MG ORAL		50,600							50,600	10,120	45,540	60,720	CAPSULE	\$ -	\$ -	100			
222	ONMEPRAZOLE MAGNESIUM TABLET DR 20 MG ORAL			10,500					3,500	14,000	2,800	12,600	16,800	TABLET	\$ -	\$ -	100			
223	ONDANSETRON HCL TABLET 8 MG ORAL	2,210		660						2,870	574	2,583	3,444	TABLET	\$ -	\$ -	100			
224	ONDANSETRON HCL/PF VIAL 2 MG/ML INTRAVEN			44	3,850					3,894	779	3,505	4,673	VIAL	\$ -	\$ -	5, 10			
225	a) PANTOPRAZOLE SODIUM TABLET DR 20 MG ORAL	5,700	42,000						800	48,500	9,700	43,650	58,200	TABLET	\$ -	\$ -	100			
	b) PANTOPRAZOLE SODIUM TABLET DR 40 MG ORAL	940,100	1,124,600				210,000		30,100	1,894,600	376,920	1,696,140	2,261,520	TABLET	\$ -	\$ -	100, 500			
226	PANTOPRAZOLE SODIUM VIAL 40 MG INTRAVEN	30		440	300					770	154	693	924	VIAL	\$ -	\$ -	10			
227	PAROXETINE HCL TABLET 10 MG ORAL		9,300							9,300	1,860	8,370	11,160	TABLET	\$ -	\$ -	100			
228	PAROXETINE HCL TABLET 20 MG ORAL		29,800							29,800	5,960	26,820	35,760	TABLET	\$ -	\$ -	100			
229	PAROXETINE HCL TABLET 30 MG ORAL		5,100							5,100	1,020	4,590	6,120	TABLET	\$ -	\$ -	100			
230	PERINDOPRIL ERBUMIN/INDAPAMIDE TAB 4-1.25MG ORAL	390	11,970							12,360	2,472	11,124	14,832	TABLET	\$ -	\$ -	30			
231	PERINDOPRIL ERBUMIN/INDAPAMIDE TAB 8MG-2.5MG ORAL	600	19,410							20,040	4,008	18,036	24,048	TABLET	\$ -	\$ -	30			
232	PERINDOPRIL ERBUMINE TABLET 2 MG ORAL	3,390	29,460						350	33,200	6,640	29,880	39,840	TABLET	\$ -	\$ -	30			
233	PERINDOPRIL ERBUMINE TABLET 4 MG ORAL	2,430	51,180						700	54,310	10,862	48,879	65,172	TABLET	\$ -	\$ -	30			
234	PERINDOPRIL ERBUMINE TABLET 8 MG ORAL	5,460	30,450						1,500	37,440	7,488	33,696	44,928	TABLET	\$ -	\$ -	30			
235	PHENTOLIN SODIUM VIAL 50 MG/ML INTRAVEN			3300	240					570	114	513	684	VIAL	\$ -	\$ -	10			
236	POLYETHYLENE GLYCOL 3350 POWDER 17G/DOSE ORAL	54	5,060							5,114	1,023	4,603	6,137	BOTTLE	\$ -	\$ -	1			
237	PRAZOSIN HCL TABLET 1 MG ORAL	22,900	92,200							114,700	22,940	103,230	137,640	TABLET	\$ -	\$ -	100			
238	PRAZOSIN HCL TABLET 2 MG ORAL	47,100	67,000							114,100	22,820	102,690	136,520	TABLET	\$ -	\$ -	100			
239	PRAZOSIN HCL TABLET 5 MG ORAL	8,100	31,600							39,700	7,940	35,730	47,640	TABLET	\$ -	\$ -	100			
240	PREGABALIN CAPSULE 150 MG ORAL	75,800	60,500				140,000			276,300	55,260	248,670	331,560	CAPSULE	\$ -	\$ -	60, 100			
241	PREGABALIN CAPSULE 225 MG ORAL	200								200	40	180	240	CAPSULE	\$ -	\$ -	100			
242	PREGABALIN CAPSULE 25 MG ORAL	900	24,800							25,700	5,140	23,130	30,840	CAPSULE	\$ -	\$ -	60, 100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (7%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	All for mat sizes available from Supplier	Supplier's product number(s)
243	PREGABALIN CAPSULE 300 MG ORAL	11,160	17,700							28,860	5,772	25,974	34,632	CAPSULE	\$ -	\$ -	60, 100			
244	PREGABALIN CAPSULE 50 MG ORAL	11,160	71,700							82,860	16,572	74,574	99,432	CAPSULE	\$ -	\$ -	60, 100			
245	PREGABALIN CAPSULE 75 MG ORAL	26,800	93,000				70,000			191,800	38,360	172,620	230,160	CAPSULE	\$ -	\$ -	60, 100			
246	PROGESTERONE MICRONIZED CAPSULE E 100 MG ORAL	2,940	19,710							22,650	4,530	20,385	27,180	CAPSULE	\$ -	\$ -	30			
247	QUETIAPINE FUMARATE TAB ER 24H 150 MG ORAL	360	1,680							2,040	408	1,836	2,448	TABLET	\$ -	\$ -	60			
248	QUETIAPINE FUMARATE TAB ER 24H 200 MG ORAL	120	2,520							2,640	528	2,376	3,168	TABLET	\$ -	\$ -	60			
249	QUETIAPINE FUMARATE TAB ER 24H 300 MG ORAL	60	2,040							2,100	420	1,890	2,520	TABLET	\$ -	\$ -	60			
250	QUETIAPINE FUMARATE TAB ER 24H 50 MG ORAL	2,280					100,000			102,280	20,456	92,052	122,736	TABLET	\$ -	\$ -	60			
251	QUETIAPINE FUMARATE TABLET 100 MG ORAL	53,500	19,300				140,000		3,000	215,800	43,160	194,220	258,360	TABLET	\$ -	\$ -	100, 500			
252	QUETIAPINE FUMARATE TABLET 150 MG ORAL	4,800								4,800	960	4,320	5,760	TABLET	\$ -	\$ -	100			
253	QUETIAPINE FUMARATE TABLET 200 MG ORAL	62,500	2,800				90,000			155,300	31,060	139,770	186,360	TABLET	\$ -	\$ -	100, 500			
254	QUETIAPINE FUMARATE TABLET 25 MG ORAL	114,000	79,000				210,000		30,000	469,000	93,800	422,100	562,800	TABLET	\$ -	\$ -	100, 500			
255	QUETIAPINE FUMARATE TABLET 300 MG ORAL	48,000	800							48,800	9,760	43,920	58,560	TABLET	\$ -	\$ -	100, 500			
256	QUETIAPINE FUMARATE TABLET 50 MG ORAL	15,900								15,900	3,180	14,310	19,080	TABLET	\$ -	\$ -	100			
257	RABEPRAZOLE SODIUM TABLET DR 10 MG ORAL	3,000								3,000	600	2,700	3,600	TABLET	\$ -	\$ -	100			
258	RABEPRAZOLE SODIUM TABLET DR 20 MG ORAL	58,710	25,340							91,510	18,302	82,359	109,212	TABLET	\$ -	\$ -	100			
259	a) RAMIPRIL CAPSULE 10 MG ORAL	166,000	116,300							282,300	56,460	254,070	338,760	CAPSULE	\$ -	\$ -	100, 500			
	b) RAMIPRIL CAPSULE 15 MG ORAL	1,800	1,700							3,500	700	3,150	4,200	CAPSULE	\$ -	\$ -	100			
	c) RAMIPRIL CAPSULE 2.5 MG ORAL	51,000	53,000	2,200	9,800					116,000	23,200	104,400	139,200	CAPSULE	\$ -	\$ -	100, 500			
	d) RAMIPRIL CAPSULE 5 MG ORAL	127,500	116,500							239,000	47,800	215,100	286,500	CAPSULE	\$ -	\$ -	100, 500			
260	RANITIDINE HCL TABLET 150 MG ORAL	209,500	212,000	4,400	6,900		63,000			495,800	99,160	446,220	594,560	TABLET	\$ -	\$ -	100, 500			
261	RANITIDINE HCL TABLET 300 MG ORAL	13,200								13,200	2,640	11,880	15,840	TABLET	\$ -	\$ -	100			
262	RANITIDINE HCL VIAL 25 MG/ML INJECTION 10x2ML			220						220	44	198	264	VIAL	\$ -	\$ -	10			
263	RISPERIDONE TAB RAPIDS 0.5 MG ORAL	2,000								2,000	400	1,800	2,400	TABLET	\$ -	\$ -	100			
264	RISPERIDONE TAB RAPIDS 2 MG ORAL	1,400								1,400	280	1,260	1,680	TABLET	\$ -	\$ -	100			
265	RISPERIDONE TAB RAPIDS 3 MG ORAL	1,320								1,320	264	1,188	1,584	TABLET	\$ -	\$ -	30			
266	RISPERIDONE TAB RAPIDS 4 MG ORAL	1,200								1,230	246	1,107	1,476	TABLET	\$ -	\$ -	30			
267	a) RISPERIDONE TABLET 0.25 MG ORAL	7,500	5,800							13,300	2,660	11,970	15,960	TABLET	\$ -	\$ -	100, 500			
	b) RISPERIDONE TABLET 0.5 MG ORAL	26,500	18,700						10,000	55,200	11,040	49,680	66,240	TABLET	\$ -	\$ -	100, 500			
	c) RISPERIDONE TABLET 1 MG ORAL	26,500	10,100						1,500	40,100	8,020	36,290	48,120	TABLET	\$ -	\$ -	100, 500			
	d) RISPERIDONE TABLET 2 MG ORAL	22,300	2,100							24,400	4,880	21,960	29,280	TABLET	\$ -	\$ -	100, 500			
	e) RISPERIDONE TABLET 3 MG ORAL	9,500	1,200							10,700	2,140	9,630	12,840	TABLET	\$ -	\$ -	100, 500			
	f) RISPERIDONE TABLET 4 MG ORAL	4,600								4,600	920	4,140	5,520	TABLET	\$ -	\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	ALL for mat sizes available from Supplier	Supplier's product number(s)
268	ROSUVASTATIN CALCUM TABLET 10 MG ORAL	13,900	150,000						7,000	209,500	40,700	183,150	244,200	TABLET	\$ -	\$ -	100,500			
269	ROSUVASTATIN CALCUM TABLET 20 MG ORAL	5,200	50,000				33,800		1,900	57,100	11,420	51,990	65,520	TABLET	\$ -	\$ -	100			
270	ROSUVASTATIN CALCUM TABLET 40 MG ORAL	9,800	36,700						400	46,500	9,300	41,950	55,800	TABLET	\$ -	\$ -	100			
271	ROSUVASTATIN CALCUM TABLET 5 MG ORAL	4,900	30,000						3,000	37,500	7,500	33,750	45,000	TABLET	\$ -	\$ -	100,500			
272	SALBUTAMOL SULFATE HFA AER AD 100 MCG INHALATION 120DS	6,713	12,011	6,000	3,248	300	6,000			34,272	6,854	30,845	41,127	AEROSOL MET DS	\$ -	\$ -	1			
273	SERTRALINE HCL CAPSULE 100 MG ORAL	82,800	105,000				60,000			247,800	49,560	223,020	297,360	CAPSULE	\$ -	\$ -	100,250			
274	SERTRALINE HCL CAPSULE 25 MG ORAL	34,700	52,500							87,200	17,440	79,480	104,640	CAPSULE	\$ -	\$ -	100,250			
275	SERTRALINE HCL CAPSULE 50 MG ORAL	76,250	100,700				40,000			216,950	43,390	195,255	260,340	CAPSULE	\$ -	\$ -	100,250			
276	SILDENAFIL CITRATE TABLET 100 MG ORAL		48,500							48,500	9,700	43,650	58,200	TABLET	\$ -	\$ -	100,250			
277	SILDENAFIL CITRATE TABLET 50 MG ORAL		5,324							5,324	1,065	4,792	6,389	TABLET	\$ -	\$ -	4, 8, 100			
278	SINVASTATIN TABLET 10 MG ORAL		1,800							1,800	360	1,620	2,160	TABLET	\$ -	\$ -	100			
279	SINVASTATIN TABLET 20 MG ORAL		6,000							6,000	1,200	5,400	7,200	TABLET	\$ -	\$ -	100			
280	SINVASTATIN TABLET 40 MG ORAL		5,600							5,600	1,120	5,040	6,720	TABLET	\$ -	\$ -	100			
281	SULFAMETHOXAZOLE/TRIMETHOPRIM TAB 800-160 MG ORAL	20,610	18,800	105,000	20,300				500	165,410	33,682	148,869	198,492	TABLET	\$ -	\$ -	100,500			
282	SUMATRIPTAN SUCCINATE TABLET 100 MG ORAL	6,600	2,796							9,396	1,879	8,456	11,275	TABLET	\$ -	\$ -	6			
283	SUMATRIPTAN SUCCINATE TABLET 25 MG ORAL	254								258	52	222	310	TABLET	\$ -	\$ -	6			
284	SUMATRIPTAN SUCCINATE TABLET 50 MG ORAL	6,258	3,798							10,056	2,011	9,050	12,067	TABLET	\$ -	\$ -	6			
285	TADALAFIL TABLET 10 MG ORAL		4,800							4,800	960	4,320	5,760	TABLET	\$ -	\$ -	4, 30			
286	TADALAFIL TABLET 20 MG ORAL		24,824							24,824	4,965	22,342	29,789	TABLET	\$ -	\$ -	4, 30			
287	a) TAMUSUOSIN HCL CAP ER 24H 0.4 MG ORAL	71,200	4,800						1,000	81,000	16,200	72,900	97,200	CAPSULE	\$ -	\$ -	100			
	b) TAMUSUOSIN HCL TAB ER 24H 0.4 MG ORAL	39,900	39,600						1,000	80,100	16,020	72,090	96,120	TABLET	\$ -	\$ -	30, 100, 500			
288	TENOFOVIR DISOPROXIL FUMARATE TABLET 300 MG ORAL	2,860							400	3,250	650	2,925	3,900	TABLET	\$ -	\$ -	30			
289	TERBINAFINE HCL TABLET 250 MG ORAL	10,230	24,090							34,320	6,864	30,888	41,184	TABLET	\$ -	\$ -	30, 100			
290	a) TOPIRAMATE TABLET 100 MG ORAL	27,300	30,000							57,300	11,460	51,570	68,760	TABLET	\$ -	\$ -	60, 100			
	b) TOPIRAMATE TABLET 200 MG ORAL	1,100	8,000							9,100	1,820	8,190	10,920	TABLET	\$ -	\$ -	100			
	c) TOPIRAMATE TABLET 25 MG ORAL	41,300	71,000							112,300	22,460	101,070	134,760	TABLET	\$ -	\$ -	100			
	d) TOPIRAMATE TABLET 50 MG ORAL	600								600	120	540	720	TABLET	\$ -	\$ -	100			
291	TRAMADOL HCL TABLET 50 MG ORAL		28,500							28,500	5,700	25,650	34,200	TABLET	\$ -	\$ -	100			
292	TRAMADOL HCL TMPP 24HR 100 MG ORAL		5,200							5,200	1,040	4,680	6,240	TABLET	\$ -	\$ -	100			
293	TRAMADOL HCL TMPP 24HR 200 MG ORAL		2,900							2,900	580	2,610	3,480	TABLET	\$ -	\$ -	100			
294	TRAMADOL HCL TMPP 24HR 300 MG ORAL	200								200	40	180	240	TABLET	\$ -	\$ -	100			
295	TRAMADOL HCL/A/CETAMINOPHEN TABLET 37.5-325MG ORAL	1,700	86,000							87,700	17,540	78,930	105,340	TABLET	\$ -	\$ -	100			
296	TRAZODONE HCL TABLET 100 MG ORAL		47,200				80,000			127,200	25,440	114,480	152,640	TABLET	\$ -	\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Minimum Work Guarantee (7%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	ALL for mat sizes available from Supplier	Supplier's product number(s)
297	TRAZODONE HCL TABLET 150 MG ORAL	41,600	15,000						500	57,100	11,420	51,390	TABLET	\$ -	\$ -	100			
298	TRAZODONE HCL TABLET 50 MG ORAL	70,800	120,000	2,200			80,000		1,200	274,200	54,840	246,780	TABLET	\$ -	\$ -	100			
299	VALACYCLOVIR HCL TABLET 1000 MG ORAL	2,900	22,000		2,800					27,100	5,420	24,390	TABLET	\$ -	\$ -	100			
300	VALACYCLOVIR HCL TABLET 500 MG ORAL	25,100	92,900						400	118,400	23,680	106,560	TABLET	\$ -	\$ -	100			
301	VALSARTAN TABLET 160 MG ORAL	52,800	52,000						600	105,490	21,098	94,941	TABLET	\$ -	\$ -	100			
302	VALSARTAN TABLET 320 MG ORAL	4,200	4,000							8,200	1,640	7,380	TABLET	\$ -	\$ -	100			
303	VALSARTAN TABLET 40 MG ORAL	8,000	14,000						240	22,240	4,448	20,016	TABLET	\$ -	\$ -	100			
304	VALSARTAN TABLET 80 MG ORAL	40,740	85,000						240	125,980	25,196	113,382	TABLET	\$ -	\$ -	30, 100			
305	a) VALSARTAN/HYDROCHLOROTHAZIDE TAB 160-12.5MG ORAL	150	25,100							25,250	5,050	22,725	TABLET	\$ -	\$ -	30, 100			
	b) VALSARTAN/HYDROCHLOROTHAZIDE TAB 80-12.5MG ORAL		31,000							31,000	6,200	27,900	TABLET	\$ -	\$ -	100			
	c) VALSARTAN/HYDROCHLOROTHAZIDE TABLET 160-25MG ORAL		31,700							31,700	6,340	28,530	TABLET	\$ -	\$ -	100			
306	VANCOMYCIN HCL VIAL 1 G INTRAVEN	30			200					509	102	488	VIAL	\$ -	\$ -	10			
307	VANCOMYCIN HCL VIAL 500 MG INTRAVEN	70								70	14	63	VIAL	\$ -	\$ -	10			
308	VARENCINE TARTRATE TAB DS PK 0.5(11)-1 ORAL		47,992							47,992	9,598	43,193	TABLET	\$ -	\$ -	56			
309	VARENCINE TARTRATE TABLET 0.5 MG ORAL		1,456							1,456	291	1,310	TABLET	\$ -	\$ -	56			
310	VARENCINE TARTRATE TABLET 1 MG ORAL		57,792							57,792	11,558	52,013	TABLET	\$ -	\$ -	56			
311	VENLAFAXINE HCL CAP ER 24H 150 MG ORAL	85,000	165,300				40,000		1,000	291,300	58,260	262,170	CAPSULE	\$ -	\$ -	100, 500			
312	VENLAFAXINE HCL CAP ER 24H 37.5 MG ORAL	38,500	133,600						1,000	173,100	34,620	155,790	CAPSULE	\$ -	\$ -	100			
313	VENLAFAXINE HCL CAP ER 24H 75 MG ORAL	97,200	162,300				37,000		500	297,000	59,400	267,300	CAPSULE	\$ -	\$ -	100			
314	ZOLMIDRIPTAN TAB RAPIDS 2.5 MG ORAL	6	2,840							2,846	469	2,111	TABLET	\$ -	\$ -	6, 30			
315	ZOLMIDRIPTAN TABLET 2.5 MG ORAL	404	3,510							4,008	802	3,607	TABLET	\$ -	\$ -	6, 30			
316	ZOLPIDEM TARTRATE TAB SUBL 10 MG SUBLINGUAL		17,460							17,460	3,492	15,714	TABLET	\$ -	\$ -	30			
317	ZOLPIDEM TARTRATE TAB SUBL 5 MG SUBLINGUAL		25,200							25,200	5,040	22,680	TABLET	\$ -	\$ -	30			
318	ZOPICLONE TABLET 5 MG ORAL	600	45,600						500	46,700	9,340	42,030	TABLET	\$ -	\$ -	100			
319	ZOPICLONE TABLET 7.5 MG ORAL	2,900	261,500				100,000		1,000	365,000	73,000	328,500	TABLET	\$ -	\$ -	100, 500			
320	a) AMOXICILLIN CAPSULE 500 MG ORAL	21,500	101,800	148,200	60,100				200	331,800	66,360	298,620	CAPSULE	\$ -	\$ -	100, 500			
	b) AMOXICILLIN CAPSULE 500 MG ORAL	21,500	101,800	148,200	60,100		40,000		200	379,800	75,960	341,820	CAPSULE	\$ -	\$ -	100, 500			
321	a) AZITHROMYCIN TABLET 250 MG ORAL	3,300	35,800	4,400	8,800					52,300	10,460	47,070	TABLET	\$ -	\$ -	6, 100			
	b) AZITHROMYCIN TABLET 250 MG ORAL	3,300	35,800	4,400	8,800		330,000			382,300	76,460	344,070	TABLET	\$ -	\$ -	6, 100			
322	a) CEFIXIME TABLET 400 MG ORAL	300		6,010		1,200				7,600	1,520	6,840	TABLET	\$ -	\$ -	2, 10			
	b) CEFIXIME TABLET 400 MG ORAL	300		6,010		1,200	4,000			11,600	2,320	10,440	TABLET	\$ -	\$ -	2, 10			
323	a) DOXYCYCLINE HCL/CATE CAPSULE 100 MG ORAL	17,115	180,000	5,000	5,100					207,215	41,443	186,494	CAPSULE	\$ -	\$ -	100			
	b) DOXYCYCLINE HCL/CATE CAPSULE 100 MG ORAL	17,115	180,000	5,000	5,100		200,000			407,215	81,443	366,494	CAPSULE	\$ -	\$ -	100			

Item #	Description	CSC Qty	DND Qty	ISC/MB Qty	ISC/ON Qty	ISC/AB Qty	ON Qty***	MB Qty	PEI Qty	Total Estimated Quantities	Overage	Minimum Work Guarantee (75%)	Maximum Total Estimated Quantities (A)	Unit of Measure (U of M)	Firm Price per U of M* (B)	Total Extended Price (C)	Canada's Preferred pack size **	DIN	ALL format sizes available from Supplier	Supplier's product number(s)
324	a) RIFAMPIN CAPSULE 150 MG ORAL			2,200				2,300	300	4,800	960	4,320	5,760	CAPSULE		\$ -	100			
	b) RIFAMPIN CAPSULE 150 MG ORAL			2,200			80,000		300	84,800	16,960	76,220	101,760	CAPSULE		\$ -	100			
325	a) RIFAMPIN CAPSULE 300 MG ORAL	890						84,000	200	85,130	17,026	76,617	102,156	CAPSULE		\$ -	100			
	b) RIFAMPIN CAPSULE 300 MG ORAL	890					450,000	84,000	200	535,130	107,026	481,617	642,156	CAPSULE		\$ -	100			

*The unit price contained in Column B will be multiplied by the total quantity in Column A to give a total extended price in Column C (ex: A x B = C). The price per unit of measure must remain the same regardless of format size.]]
As an example, if the unit price per tablet was \$0.25 it would remain the same for a bottle of 100's (\$25.00) or for a bottle of 200's (\$50.00).

**The format size indicated in this column are to provide suppliers with an indication of the most commonly ordered bottle/pack sizes by the identified Users and in no way represents a commitment on the part of Canada.
Identified Users reserve the right to order additional format sizes available but not listed in this column.

***Ontario (Ministry of Health and Long Term Care) has format size requirements in order to run their program. As such, should the Bidder with the lowest price per item not have Ontario's required format size available, Canada reserves the right to award Ontario's quantities to the next lowest Bidder per item who can meet the format size required by Ontario. Please see Annex A 2 attached for Ontario's format requirements.

Items 17, 38, 111, 137, 182, 193, 225, 259, 267, 287, 290, and 305 will be evaluated by the lowest aggregate price per grouping for that item.